CURRICULUM VITAE: MARC STEPHEN RENDELL, M.D.

ADDRESS: The Rose Salter Medical Research Foundation
34 Versailles
Newport Coast, CA 92657-0065

clinic office 355 Placentia Avenue, Suite 308b
Newport Beach, CA 92663

TELEPHONE: 402 -578-1580

HOSPITAL AND FACULTY APPOINTMENTS:

12/1977-6/1983 Active Staff and Assistant Professor
Division of Endocrinology
Department of Medicine
The Johns Hopkins Hospital
Baltimore, Maryland

6/1980-6/1983 Assistant Professor
Division of Nuclear Medicine
Department of Radiology
The Johns Hopkins University
School of Medicine
Baltimore, Maryland

12/1977-6/1983 Chief, Endocrinology
Director, Radioimmunoassay Laboratory
The US Public Health Service Hospital
Baltimore, Maryland

7/1983-11/1984 Director, Diabetes Institute
City of Faith Medical and Research Center
Associate Professor, Medicine and Pathology
ORU School of Medicine
Tulsa, Oklahoma

2/1985- 9/2016 Director, Creighton Diabetes Center
Associate Professor of Medicine
Associate Professor of Biomedical Sciences (1993-1995)

Professor of Medicine and Biomedical Sciences (1996-2016)
Creighton University School of Medicine
Omaha, Nebraska

3/1999- Medical Director: Rose Salter Medical Research Foundation
Baltimore, Maryland, Omaha, Nebraska, Newport Beach, California

CLINICAL PRACTICE

12/1977-6/1983 Active Staff
Division of Endocrinology
Department of Medicine
The Johns Hopkins Hospital
Baltimore, Maryland

12/1977-6/1983 Chief, Endocrinology
Director, Radioimmunoassay Laboratory
The US Public Health Service Hospital
Baltimore, Maryland

7/1983-11/1984 Director, Diabetes Institute
City of Faith Medical and Research Center
ORU School of Medicine
Tulsa, Oklahoma

2/1985- 9/2016 Director, Creighton Diabetes Center
Creighton University Medical Center
Omaha, Nebraska

9/2016- Medical Director: Rose Salter Diabetes Center
Newport Beach, California

1/2017- Telemedicine Physician
Teladoc and MDLive

EDUCATION:

9/1964-6/1968 B.S. Magna Cum Laude, Honors Chemistry
CUNY, New York 1964-1968

7/1968-5/1972 M.D., Cum Laude

SUNY Downstate Medical Center 1968-1972

POST DOCTORAL EDUCATION:

7/1972-6/1973 Resident I, Internal Medicine
Lenox Hill Hospital, New York, N.Y.

7/1973-6/1975 Research Associate
National Cancer Institute
Bethesda, Maryland

7/1975-6/1976 Resident II, Internal Medicine
U. of Connecticut Medical School
Farmington, Connecticut

7/1976-11/1977 Clinical Fellow
Endocrinology and Metabolism
U. of Miami Medical School
Miami, Florida

MILITARY SERVICE:

7/1973-6/1975 Surgeon, USPHS
Station: National Institutes of Health
Bethesda, Maryland

12/1977-9/1981 Senior Surgeon, USPHS
Station: Johns Hopkins Hospital
and the USPHS Hospital, Baltimore

ADMINISTRATIVE:

1/1979-12/1983 Member, Board of Directors
American Diabetes Association
Maryland Affiliate

6/1978-9/1981 Director, Clinical Investigations Unit
USPHS Hospital, Baltimore

6/1980-9/1981 Director, Radioimmunoassay Laboratory
USPHS Hospital, Baltimore

7/1983-11/1984	Director, Radioimmunoassay Section Pathology Department City of Faith Medical and Research Center
7/1983-11/1984	Director, Diabetes Institute City of Faith Medical and Research Center
2/1985-9/2016	Director, Creighton Diabetes Center
1/1986-1/1990	Member, Board of Directors American Diabetes Association Nebraska, Affiliate
1/1992-1/1995	Member, Research Committee American Heart Association Nebraska Affiliate
1/1995-1/1998	American Heart Association Affiliate Grant Review Study Section
6/1993	Member of NIH Site Visit Team: Univ of W Virginia GCRC
1/1993-1/1995	Member of the HCFA Nebraska PRO Provider Quality Initiative Committee (PQIC)
12/1999- present	Medical Director: Rose Salter Medical Research Foundation
11/2000- present	Executive Director: Association of Diabetes Investigators
6/2009-	Member Advisory Committee Center for Device Evaluation and Radiological Health (CDRH) Medical Devices Advisory Committee Staff (ACS) US Food and Drug Administration

SPECIALTY CERTIFICATIONS:

6/22/1977	Diplomate, Internal Medicine American Board of Internal Medicine
6/19/1979	Diplomate, Endocrinology and Metabolism American Board of Internal Medicine
4/20/1990	Diplomate, Geriatric Medicine American Board of Internal Medicine
5/01/2004	Certified Diabetes Educator

HONORS, SCHOLARSHIPS:

9/1964-6/1968 New York State Regents Scholarship

9/1968-6/1972 CUNY Dr. Jonas Salk Medical Scholarship

9/1968-6/1972 New York State Regents Medical Scholarship

1972 Honors Day Winner, Downstate Medical Center

LICENSURES:

7/1973 National Board of Medical Examiners

7/1973 Maryland D15908 (inactive)

7/1975 Florida ME 27080 (inactive)

11/1977 California GO 33791

7/1983 Oklahoma 14245 (inactive)

7/1990 Nevada 5936 (inactive)

2/1985 Nebraska 17167

EDITORIAL BOARDS:

1/1987-1/1991 Board of Editors, Journal of Clinical Endocrinology and Metabolism

GRANTS:

Mathematical Modeling of Insulin Binding in the IM-9 Lymphocyte. DHEW USPHS BAL 79-46 1978-1979 $16,000

The Dynamics of the Human Immune Response to Bovine and Pork Insulin. DHEW USPHS BAL 79-08; 1979-1981: $5,275

Endocrinology and Diabetes Research Program, USPHS Hospital, Baltimore. DHEW USPHS BAL 80-01; 1980-1981: $20,000

Insulin Dependence in Adult Onset Diabetes. DHEW USPHS BAL 80-53;
1980-1981: $4,000

Endocrinology and Diabetes Research Program, USPHS Hospital, Baltimore. DHEW USPHS BAL 80-01; 1981-1982: $24,000

The Safety, Tolerance and Efficacy of Oral Administration of AY27,773 in the Treatment of Symptomatic Diabetic, Peripheral, Sensorimeter Polyneuropathy. Ayerst Laboratories 81-079; 1984-1986: $238,000

The Safety, Tolerance and Efficacy of Oral Administration of AY27,773 in the Long Term Treatment of Symptomatic Diabetic, Peripheral, Sensorimeter Polyneuropathy. Ayerst Laboratories 81-113; 1985-1986: $50,000

Long Term One Year Open Label Safety Study of Acifran 200 mg b.i.d. in Type IIa Hyperlipidemia. Ayerst Laboratories 84-203; 1985-1986: $60,000

The Safety, Tolerance, and Efficacy of Oral Administration of Tolrestat(AY-27,773) in the Treatment of Moderate Non-Proliferative Diabetic Retinopathy: Effects on Retinal Morphology in Patients with Insulin Dependent and Non-Insulin Dependent Diabetes Mellitus.
Ayerst Laboratories 81-084 and 81-085; 1985-1993: $250,000

The Safety, Tolerance, and Efficacy of Oral Administration of Tolrestat(AY-27,773) in the Prevention of Non-Proliferative Diabetic Retinopathy: Effects on Retinal Morphology and Renal Function in Patients with Insulin Dependent and Non-Insulin Dependent Diabetes Mellitus. Ayerst Laboratories 84-196 and 84-197; 1985-1993: $500,000

Diabetic Retinopathy and Hypertension Screening Program: Nebraska State Health Department. 1986-1987: $18,000

Current Perception Threshold Testing in Diabetic Neuropathy:
Diabetes Research and Education Foundation. 1987-1988: $20,000

Lovostatin Multicenter Trial: Clinical Research International (Merck Sharp and Dohme). 1987-1989: $80,000

A Phase I/II Two Week Multi-Center Double Blind, Placebo Controlled Study of the Safety, Toleration and Efficacy of CP-68,722-2 in Non-Insulin Dependent Diabetes. Pfizer Inc: 1987-1988: $79,000

The Clinical Evaluation of Patients with Type II (Non-Insulin Dependent) Diabetes Mellitus Transferred From Currently Marketed DiaBeta Tablets to a Reformulated Product, Diabeta N. Hoechst-Roussel: 1988-1990: $22,000

Measurement of Current Perception Thresholds and Skin Blood Flow by Laser Doppler Flowmetry in Pentoxifylline Treated Diabetic Patients with Clinical Evidence of Sensory Diabetic Neuropathy: Hoechst-Roussel Pharmaceuticals: 1988-1989: $48,000

A Multiclinic, Double-Blind Study to Compare the Safety and Efficacy of Lovastatin and Gemfibrozil in Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM): Merck Sharp and Dohme: 1988-1990: $20,000

A Multi-Center Study of the Safety of Four Different Doses of HOE843 and Placebo in Subjects with Diabetes Mellitus: Hoechst-Roussel: 1988-1990: $350,000

A Multicenter, Randomized, Parallel Group, Double-Masked, Placebo-Controlled Study to Determine the Effect of Daily Administration of MK-538 on the Progression of Background Retinopathy in Diabetic Patients: Merck Sharp and Dohme: $106,000: 1989-1991

An Evaluation of Pentoxifylline (Trental) in the Treatment of Symptomatic Sensory Neuropathy in Patients with Type I and Type II Diabetes Mellitus: Hoechst-Roussel: 1990-1991: $120,000

Laser Doppler Measurement of Skin Blood Flow in Diabetic Hypertensive Patients Treated with Isradipine and Atenolol: Glaxo Inc and Sandoz Inc: 1990-1993: $180,000

Dose Response Study of HOE 490 (Glimepiride) in Subjects with Non-Insulin Dependent Diabetes Mellitus (NIDDM) Who Have Previously Received Sulfonylurea Agents: Hoechst-Roussel: 1990-1991: $40,000

Cell Transit Time Analysis in Diabetes: Diabetes Research and Education Foundation: 1990-1991: $20,000

Randomized, Comparative Evaluation of the Efficacy and Safety of HOE 490 vs Glipizide in Patients with Non-Insulin Dependent Diabetes Mellitus: Hoechst-Roussel: 1992-19931: $100,000

Double Blind Randomized Comparison of Cozaar and Hyzaar vs Vasotec in Treatment of Patients with Mild to Moderate Hypertension. Merck Inc: 1994-1995: $12,000

Skin Blood Flow as a Peripheral Vascular Response: American Heart Association, Nebraska Affiliate: 1992-1993: $19,993

A Stratified, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of Cronassial in Diabetic Polyneuropathy. Fidia Pharmaceutical: 1992-1994: $275,000

A Multicenter, 12 week, Double-Blind, Placebo-Controlled, Dose Response Study of CI-991 in Patients with Non-Insulin Dependent Diabetes Mellitus. Parke-Davis Pharmaceutical: 1993 $120,000

An Open-Label, Positive Controlled, 48 Week, Multicenter Study of Troglitazone (CI-991) in Patients with Non-Insulin Dependent diabetes Mellitus to Assess Potential Effects on Cardiac Mass and Function. Parke Davis Pharmaceutical: 1994-1996: $205,000

A Phase II, Multicenter, double Blind, Placebo Controlled, Parallel Group Study of the Safety and Efficacy of Recombinant Human Nerve Growth Factor (rhNGF) in Patients with Diabetic Peripheral Polyneuropathy. Genentech: 1995-1996: $215,000

A Randomized, Double Blind, Placebo controlled Study of the

Effect of Cilostazol in Patients with Intermittent Claudication Secondary to Peripheral Vascular Disease. Otsuka Inc: 1994-1996: $120,000

A 12 week Multicenter, Double Blind, Placebo Controlled Study Assessing the Safety, tolerability and Efficacy of BRL 49653C in Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM). Smith Kline Beecham: 1995-1996: $145,000

A Multicenter, Double Blind, Placebo Controlled Parallel Group Study of the Effects of Oral Zopolrestat in Normotensive, type I diabetes with Incipient Nephropathy (Microalbuminuria). Pfizer Inc: 1994-1996: $17,000

A Placebo Controlled, Double Blind, Randomized Three Month Maintenance Study of Repaglinide in Treatment of Patients with Type II diabetes. Novo Nordisk : 1994-1995: $40,000

Multi-Center, Double Blind, Placebo Controlled Parallel Group Comparison Study to Investigate the Efficacy and Safety of Acarbose (BAY G5421) in the Treatment of Patients with Non-Insulin Dependent Diabetes Mellitus (Type II) Inadequately Controlled Insulin. Bayer Pharmaceutical Inc: 1996-1997: $70,000

A Multicenter double Blind, Randomized, Parallel Group, Dose Ranging Study to Compare the Efficacy, Safety and Tolerability of Four Fixed Dose Levels of SDZ DJN 608 and Placebo in Diet-Treated Patients with Non-Insulin Dependent Diabetes Mellitus. Sandoz Pharmaceuticals Inc: 1996-1997: $40,000

A Multicenter, Double blind, Randomized, combination Study to Prospectivley Evaluate the Safety and Efficacy of Two Oral Fixed Doses of SDZ DJN 608 Plus Glyburide Compared to Placebo Plus Glyburide in Subjects with Non-Insulin Dependent Diabetes Mellitus. Sandoz Pharmaceuticals Inc: 1996-1997: $30,000

A Phase II, Randomized, Double-Blind Placebo-Controlled, Multidose Study of the Safety and Pharmacokinetic/Pharmacodynamic Effects of RHIGF-I in Combination with Insulin for the Treatment of Type II Diabetes Mellitus. Genentech Inc: 1996-1997: $140,000

LIFE (Losartan Intervention for Endpoint Reduction in Hypertension) A Triple Blind Parallel Study to Investigate the Effect of Losartan versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients with Left Ventricular Hypertrophy. Merck Inc: 1996-1999: $5,000

A Double-Blind, Randomized, Placebo-Controlled Parallel Group Multicenter, Flexible dose Escalation Study to Assess the Efficacy and Safety of Sildenafil Administered as Required to Male Diabetic Patients with Erectile Dysfunction. Pfizer Inc: 1996-1999: $20,000

A Double-Blind, Randomized, Placebo-Controlled Parallel Group Multicenter, Flexible dose Escalation Study to Assess the Efficacy and Safety of Sildenafil Administered as Required to Male Patients with

Erectile Dysfunction. Pfizer Inc: 1996-1999: $20,000

Dose-Response Study of the Analgesic Effect of LY303870 in Patients with Diabetic Neuropathy Pain. Eli Lilly: 1996: $55,000

A Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Trial of 0.1, 0.5, 1, 2, 5 mg TID of Voglibose (AO-128) in Type II Diabetes Mellitus Patients (Non-Insulin Dependent Diabetes Mellitus, NIDDM) Takeda Inc: 1996-1998: $36,000

A 52-Week Open Label, Multicenter, Active (Glyburide) Comparison Study, to Evaluate the Effect of BRL49653C on Cardiovascular Function in Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM). SmithKline Beecham Pharmaceuticals: 1996-1999: $120,000

A Randomized, Double-Blind, Placebo-Controlled, Six-Month Safety and Efficacy Trial of Voglibose (AO-128) 2 mg TID as Adjunctive Therapy to a Sulfonylurea Compared to a Sulfonylurea Alone in Type II Diabetes Mellitus Patients (Non-Insulin Dependent Diabetes Mellitus (NIDDM): Takeda Inc: 1997-1998: $30,000

A 6 Month, Double-Blind, Placebo-Controlled, Multicenter Study of Troglitazone in Patients with Type II Diabetes and Congestive Heart Failure. Warner Lambert Inc: 1997-1999: $25,000

Effects of Prowashonupana Barley on Glycemic Response to a Test Meal in Non-Insulin Dependent Diabetes. ConAgra Inc: 1997-1998: $85,000

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Multidose
Study of the Combined Effects of Subcutaneously Administered Insulin and rh-IGF-I in Subjects with Insulin Dependent Diabetes Mellitus. Genentech Inc: 1997-1998: $9,000

A Phase III, Multicenter, Double-Blind, Placebo Controlled, Parallel Group Study of the Efficacy and Safety of Recombinant Human Nerve Growth Factor (RHNGF) in Subjects with Diabetic Neuropathy. Genentech Inc: 1997-1999: $156,000

A 12-Week, Multicenter Double-Blind, Parallel, Positive-Controlled, Dose-Titration Study of Teveten (Eprosartan Mesylate, SKF 108566J) Compared to Enalapril in Patients with Severe Systolic Hypertension. SmithKline Beecham Pharmaceuticals: 1997-1998: $30,000

A Double-Blind, Placebo-Controlled, Randomized Study of the Safety and Efficacy of a Combination of Sulfonylurea and Two Doses of Pioglitazone (15 or 30 mg) in the Treatment of Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM): Takeda Inc: 1997-1999: $70,000

A Double-Blind, Placebo-Controlled, Randomized Study of the Safety and Efficacy of a Combination of Metformin and 30 mg of

Pioglitazone in the Treatment of Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM): Takeda Inc: 1997-1999: $40,000

A Double-Blind, Placebo-Controlled, Randomized Study of the Safety and Efficacy of a Combination of Insulin and Two Doses of Pioglitazone (15 or 30 mg) in the Treatment of Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM): Takeda Inc: 1997-1999: $24,000

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Effects of Subcutaneous R-Methuleptin on Glycemic Control in Obese Subjects with Diet-Treated Non-Insulin Dependent Diabetes Mellitus. Amgen Inc: 1997-1999: $40,000

A Comparison of the Efficacy, Tolerability, and cost of Amaryl Alone, Metformin Alone, or a Combination of Lower Doses of Amaryl and Metformin in Patients with Recent Onset type 2 Diabetes Mellitus (NIDDM). Heochst Marion Roussel, Inc: 1997-1999: $40,000

A Multicenter, Open Label, Fixed Dose Extension to Study B356-E-00 to Prospectively Evaluate the Log-Term Safety and Tolerability of CDJN608 Monotherapy in Subjects with Non-Insulin Dependent Diabetes Mellitus Inadequately Controlled with Diet Alone. 1997-1998: $80,156

An 8 Week, Double-Blind, Placebo-Controlled, Parallel, Multicenter, Ambulatory Blood Pressure Monitoring (ABPM) Comparison of Teveten (Eprosartan Mesylate SKF 108566J) 600 and 1200 mg Once Daily in Patients with Essential Hypertension. SmithKline Beecham Pharmaceuticals: 1996-1998: $28,000

Double Blind Efficacy and Safety Study of Two Doses of Baycol (Cerevastatin) and Pravachol (Pravastatin) in the Treatment of Patients with Primary Hypercholesterolemia. SmithKline Beecham Pharmaceuticals: 1998: $38,000

A Double-Blind Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Effects of Pramlintide (AC137) on Glycemic Control as Determined by Glycated Hemoglobin in Patients with Type I Diabetes Mellitus. Amylin Pharmaceuticals: 1998-1999: $29,000

A Double-Blind Placebo-Controlled, Multicenter, Phase III Study to Evaluate the Effects of Pramlintide (AC137) on Glycemic Control as Determined by Glycated Hemoglobin in Patients with Type II Diabetes Mellitus. Amylin Pharmaceuticals: 1998-1999: $19,000

A Multicenter, Double-Blind, Randomized, Parallel-Group Study to Compare the Efficacy, Tolerability and Safety of SDZDJN 608 Monotherapy, Troglitazone Monotherapy and combination of SDZDJN 608 and Troglitazone to Placebo in Subjects with Non-Insulin Dependent Diabetes Mellitus. Novartis Pharmaceuticals Inc: 1998-1999: $10,000

Effect of Repaglinide Added to Maximal Dose Glyburide in the Treatment of Patients with NIDDM. Novo Nordisk Inc: 1998-1999: $30,000

A 5 Week Double Blind Placebo-Controlled Trial of 3 Dosages of Pregabalin (75, 300, and 600 mg/day) for Treatment of Patients with Painful Diabetic Peripheral Neuropathy. Warner Lambert Inc: 1998-1999: $26,000

An Open, Non-Comparative Extension Study of Sildenafil in Patients with Erectile Dysfunction. Pfizer Inc.: 1997-2001: $54,000

An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of BRL 49553C When Administered as Monotherapy, Twice Daily, to Patients with Non-Insulin Dependent Diabetes Mellitus. SmithKline Beecham: 1997-2001: $60,480

A 6-Month, Double-Blind, Placebo-Controlled, Multicenter Stgudy of Troglitazone (CI-991) in Patients With Type 2 Diabetes and Congestive Heart Failure. Parke-Davis: 1997-2000: $25,200

Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2a); A randomized, placebo-controlled, double-blind, multi-center long-term trial with two parallel groups. ASTAMedica: 1997-2001: $176,328

Assessment of Efficacy and Safety of Thioctic Acid in the Intravenous Treatment of Symptomatic Diabetic Polyneuropathy; A randomized, placebo-controlled, double-blind, multi-center trial with two parallel groups. ASTAMedica: 1997-2001: $74,525

A 3-Year Open-Label, Multicenter, Active (Glyburide) Comparison Study to Evaluate the Effect of BRL 49653C 8 mg uid on Cardiovascular Function in Patients with Non-Insulin Dependent Diabetes Mellitus (NIDDM). SmithKline Beecham: 1997-2001: $27,412

An Open-Label Extension Study to Assess the Long-Term Safety, Tolerability and Efficacy of BRL49563C When Administered Once or Twice Daily in Combination with Glyburide to Patients with Non-Insulin Dependent Diabetes Mellitus. SmithKline Beecham: 1997-2001: $53,481

An Open-Label Extension Study to Assess the Long-Term Safety, Tolerablilty and Efficacy of BRL49653 When Administered Once or Twice Daily in Combination with Insulin to Patients with Non-Insulin Dependent Diabetes Mellitus. SmithKline Beecham: 1997-2001: $24,720

Pregabalin Open-Label, Extension Safety Trial in Patients With Chronic Pain. Parke-Davis: 1997-2001: $131,150

Open-Label Long-Term Extension Study Pioglitazone in Patients With Type 2 Diabetes Mellitus. Takeda: 1998-1999: $88,676

Double-Blind Randomized Study of the Safety and Efficacy of a Combination of Metformin and 45 mg of Actos (pioglitazone HCI) Compared to a Combination of Metformin and 30 mg of Actos (pioglitazone HCI) in the Treatment of Patients with Type 2 Diabetes. Takeda Pharmaceuticals: 1998-2000: $47,120

A Double-Blind, Placebo-Controlled, Randomized Trial to Determine the Effects of a Range of Doses of Metformin Novel Oral Dose Form (Biphasic Tablet) Administered Either Once or Twice a Day in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control with Diet and Excercise. Bristol-Myers Squibb: 1998-2001: $58,140

Phase II Double-Blind Randomized Placebo-Controlled 28-Day Tolerability and Preliminary Efficacy Study of Six Different Doses of VX-853 Administered to Patients with Diabetic Peripheral Neuropathy. Vertex: 1998-1999: $45,156

Efficacy and Safety of Inhaled Compared with Subcutaneous Human Insulin Therapy in Subjects with Type 1 Diabetes Mellitus: A Six-month, Outpatient, Parallel Comparative Trial. Pfizer Inc.: 1998-2000: $35,665

Efficacy and Safety of Inhaled Compared with Subcutaneous Human Insulin Therapy in Subjects with Type 2 Diabetes Mellitus: A Six Month, Outpatient, Parallel Comparative Trial. Pfizer Inc.: 1998-2000: $39,814

Efficacy and Safety of Inhaled Human Insulin Therapy in Subjects with Type 2 Diabetes Mellitus Not Well Controlled with Combination Oral Agents: A Three-month, Outpatient, Parallel Comparative Trial. Pfizer Inc.: 1998-2000: $4,206

A 24-Week, Double-Blind Study of Troglitazone (Rezulin) in Combination With Sulfonylurea or in Combination With Sulfonylurea Plus Metformin in Type 2 Diabetes Patients Inadequately Controlled on Sulfonylurea Plus Metformin. Parke-Davis: 1998-2001: $40,316

A Randomized, Double Blind, Placebo-Controlled, Dose Titration Study of V20001 in Type 2 Diabetic Patients Treated Only with Diet and/or Exercise. Purdue-Pharma: 1999-2001: $82,338

A 26-Week Randomized, Double-Blind, Parallel Group Sudy to Compare the Efficacy, Safety and Tolerability of Rosiglitazone (2 mg BID and 4 mg BID) Versus Placebo in Combination with Glyburide and Metformin in Patients with Type 2 Diabetes Mellitus. SmithKline Beecham: 1998-2000: $26,558

A Twenty-four Week, Randomized, Double-Blind Study of the Effects of Pletal (cilostozol) versus Trental (pentoxitylline) and Placebo Administered Orally to Patients with Intermittent Claudication Secondary to Peripheral Arterial Disease. Otsuka: 1999-2000: $91,275

An Open Study of the Chronic Administration of Cilostazol (OPC-13013) in Patients with Intermittent Claudication Secondary to Chronic Occlusive Arterial Disease. Otsuka: 1999-2000: $47,454

Long Term Safety of Inhaled Insulin Extension of Therapy in Subjects with Type 1 or Type 2 Diabetes Mellitus Completing Phase III Randomized Treatment Trials. Pfizer, Inc.: 1999-2003: $61,416

Target Glycemic Control and the Incidence of Synptomatic Nocturnal Hypoglycemia in Insulin Naive Subjects with Type 2 Diabetes on

Oral Hypoglycemic Agent(s) and Treated with Insulin Glargine or NPH Human Insulin. Aventis: 1999-2002: $48,000

A Randomized, Double-Blind Study to Compare the Durability of Glucose Lowering and Preservation of Pancreatic Beta-Cell Function of Rosiglitazone Monotherapy Compared to Metformin or Glyburide/Glibenclamide in Patients with Drug Naive, Recently Diagnosed Type 2 Diabetes Mellitus. SmithKline Beecham: 2000: $84,060

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Fixed Dose, Parallel Group, Three Month Comparison Study to Investigate the Efficacy and Safety of the Phosphodiestrerase Type V Inhibitor BAY 38-4956 in Males with Erectile Dysfunction and With Diabetes Mellitus. Bayer: 2000-2001: $46,740

A Dose Titration, Extension Study of Open-Label V20001 in Type 2 Diabetic Patients Who Have Withdrawn Prematurely from Study KD98-0603 Due to Lack of Efficacy. Purdue Pharma: 2000: $34,184

Dose Finding, Efficacy, Safety and Pharmocokinetic of AR-HO39242XX in Patients with Type 2 Diabetes. AstraZeneca: 2001-2002: $197,820

A Multicenter, Randomized, Double-Blind Clinical Trial Comparing the Safety and Efficacy of Metformin/Glyburide Tablets to Metformin Plus Rosiglitazone Therapy in Patients with Type 2 Diabetes Mellitus who Have Inadequate Glycemic Control with Metformin Monotherapy. Bristol-Myers Squibb: 2000-2002: $16,088

Effect of Gymnema Sylvestra Added to Oral Hypoglycemic Regimens in the Treatment of Patients with NIDDM. Win-Cen Marketing: 2000-2001: $14,000.

A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Evaluate the Role of the Addition of Amaryl to NIDDM Patients Not Responding to Maximum Dose Metformin and Thiazolidinedione Therapy. Aventis: 2000-2003: $40,000

The Safety and Efficacy of PNU-182716 versus Rosiglitazone: A One-year, Randomized, Double Blind, Parallel Group, Active Comparator Study. Pharmacia & Upjohn: 2000-2002: $36,000

A Prospective Randomized, Double Blind Multicenter Trial Assessing the Safety and Efficacy of Sequential (intravenous/oral) BAY 12-8039 (moxifloxacin) 400 mg Every 24 hr Compared to Intravenous Piperacillin/Tazobactam 3.0/3.75 Oral Amoxicillin/Clavulanic Acid Suspension 800 mg Every 12 hr for the Treatment of Patients with Complicated Skin and Skin Structure Infections. Bayer: 2000-2004: $52,920

A Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the Efficacy and Safety of Topiramate Versus Placebo in the Treatment of Pain Associated with Diabetic Peripheral Polyneuropathy. RWJohnson: 1999-2002: $59,420

Target Glycemic Control and the Incidence of Symptomatic Nocturnal Hypoglycemia in Insulin Naive Subjects with Type 2 Diabetes on Oral Hypoglycemic Agent(s) and Treated with Insulin Glargine or NPH Human Insulin. Aventis: 1999-2002: $48,000

Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Fixed Dose, Parallel Group, Three Month Comparison Study to Investigate the Efficacy and Safety of the Phosphodiestrerase Type V Inhibitor BAY 38-4956 in Males with Erectile Dysfunction and With Diabetes Mellitus. Bayer: 2000-2001: $46,740

Dose-Finding Trial on the Anti-Diabetic Properties of Dexlipotam in Patients with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study with Four Parallel Groups. ASTAMedica: 2000-2003: $42,600

Efficacy, Dose-Ranging, and Safety For RWJ-241947 in Type 2 Diabetic Subjects Inadequately Controlled on Diet, Metformin, or Sulfonylurea: A 24 Week Double-Blind Randomized Placebo Controlled Study. RWJohnson: 2000-2001: $65,700

Dose Finding, Efficacy, Safety and Pharmacokinetic of AR-HO39242XX in Patients with Type 2 Diabetes. AstraZeneca: 2001-2002: $197,820

A Multicenter, Randomized, Double-Blind Clinical Trial Comparing the Safety and Efficacy of Metformin/Glyburide Tablets to Metformin Plus Rosiglitazone Therapy in Patients with Type 2 Diabetes Mellitus who Have Inadequate Glycemic Control with Metformin Monotherapy. Bristol-Myers Squibb: 2000-2002: $16,088

Effect of Gymnema Sylvestra Added to Oral Hypoglycemic Regimens in the Treatment of Patients with NIDDM. Win-Cen Marketing: 2000-2001: $14,000.

A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Evaluate the Role of the Addition of Amaryl to NIDDM Patients Not Responding to Maximum Dose Metformin and Thiazolidinedione Therapy. Aventis: 2000-2003: $40,000

The Safety and Efficacy of PNU-182716 versus Rosiglitazone: A One-year, Randomized, Double Blind, Parallel Group, Active Comparator Study. Pharmacia & Upjohn: 2000-2002: $36,000

Omnipatrilat Cardiovascular Treatment Assessment Versus Enalapril (OCTAVE). Bristol-Myers Squibb: 2000-2001: $22,500

A Prospective Randomized, Double Blind Multicenter Trial Assessing the Safety and Efficacy of Sequential (intravenous/oral) BAY 12-8039 (moxifloxacin) 400 mg Every 24 hr Compared to Intravenous Piperacillin/Tazobactam 3.0/3.75 Oral Amoxicillin/Clavulanic Acid Suspension 800 mg Every 12 hr for the Treatment of Patients with Complicated Skin and Skin Structure Infections. Bayer: 2000-2004:

$52,920

A 6-week, Open-Label, Dose-comparison Study to Evaluate the Safety and Efficacy of Rosuvastatin (ZD4522) Versus Atorvastatin, Cerivastatin, Pravastatin, and Simvastatin in Subjects with Hypercholesterolemia. AstraZeneca: 2001-2002: $35,000

Evaluation of Diabetic Retinopathy Progression in Subjects with Type 2 Diabetes Mellitus Treated with Insulin - HOE901/4016. Aventis: 2001-2006: $183,870

Effects of Oral NO-1886 on Lipoproteins in Subjects with Type II Diabetes Mellitus who are Receiving Statin Therapy. TAP Pharmaceuticals: 2001-2003: $40,560

A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study of V20001 in Type 2 Diabetic Patients - KAD-1229 US02-01. Kissei Pharma USA, Inc: 2002-2003: $117,720

26-week, multinational, multicenter, controlled, open 1:1 randomized, parallel clinical trial comparing HMR 1964 with regular human insulin injected subcutaneously in subjects with type 2 diabetes mellitus also using NPH insulin, and which will lead into a comparative 26-week safety extension study (HMR 1964/3012) - HMR 1964/3002. Aventis Pharmaceuticals: 2002-2003: $40,860

Double-blind Comparison of Memantine and Placebo in the Treatment of Chronic Pain in Patients with Diabetic Neuropathy - MEM-MD-06A and Open-label Extension of Memantine Treatment in Patients with Painful Diabetic Neuropathy - MEM-MD-06B. Forest Laboratories, Inc.: 2002-2003: $161,000

12 week, multinational, multicenter, controlled, open 1:1:1 randomized, parallel clinical trial to assess noninferiority between pre- and post-meal administration of HMR 1964 and pre-meal regular human insulin in subjects with type I diabetes mellitus receiving insulin glargine as the basal insulin therapy - HMR1964A/3004. Aventis Pharmaceuticals: 2002-2003: $34,550

Safety and Efficacy of Propionyl L-Carnitine in Peripheral Arterial Disease (Intermittent Claudication) as Assessed by a Fixed Treadmill Protocol in a Diabetic Population. Sigma-Tau Research, Inc.: 2002-2004: $51,600

A multinational randomized, double-blind, placebo-controlled, force-titration, 2 X 2 factorial design study of the efficacy and safety of long term administration of nateglinide and valsartan in the prevention of diabetes and cardiovascular outcomes in subjects with impaired glucose tolerance (IGT). Novartis: 2001-2009: $246,624

Pregabalin Open-Label Trial in Chronic Pain Patients Meeting Treatment-Refractory Patients - 1008-197. Pfizer: 2001-2003: $19,800

Open-label, Randomized, Multi-center Phase IIIb, Parallel Group

Switching Study to Compare the Efficacy and Safety of Lipid Lowering Agents Atorvastatin and Simvastatin with Rosuvastatin in High Risk Subjects with Type IIA and IIB Hypercholesterolemia. AstraZeneca. 2001-2003: $31,000

26-week, multinational, multicenter, open, clinical extension trial to assess one year safety of HMR1964 compared with regular human insulin injected subcutaneously in subjects with type 2 diabetes mellitus also using NPH insulin, and previously participating in study HMR 1964A/3002. Aventis Pharmaceuticals. 2002: $14,140

A Six-Month Open Label, Randomized Parallel Group Trial Assessing the Impact of Dry Powder Inhaled Insulin (Exubera) on Glycemic Control Compared to Insulin Glargine (Lantus) in Patients with Type 2 Diabetes Mellitus Who are Poorly Controlled on a Combination of Two or More Oral Agents - A2171095. Pfizer Inc. 2007 - 2008: $30,684

Effects of RO0728804 On Renal Function in Patients with Type 2 Diabetes, As Compared to Actos - BC20653A. Roche Laboratories Inc. 2007 - 2009: $51,986

A 2-Month Safety Follow-Up Trial of Subjects from MannKind Protocols MKC-TI-009, MKC-TI-102, MKC-TI-103 and MKC-TI-030 - MKC-TI-126. MannKind Corporation. 2007 - 2008: $8,992

An Open-Label, Multi-Center, Follow-On Study examining the Long-Term Safety and Efficacy of Insulin VIAJECT in Subjects with Type 1 Diabetes mellitus. VIAJECT 07J. Biodel Inc. 2007 - 2008: $23,704

An Open-Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAJECT and Regular Human Insulin in Patients with Type 2 Diabetes Mellitus - VIAJECT 08J. Biodel Inc. 2007 - 2008: $32,104

An Open-Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAJECT in Subjects with Type 2 Diabetes Mellitus - VIAJECT 09J. Biodel Inc. 2007 - 2008: $23,380

A Phase 2b, Randomized, Double-Blind, Parallel-Group, Study of Safety and Efficacy of 16 Weeks of Treatment with DIO-902 or DIO-902 Placebo in Addition to Metformin and Atorvatatin or Atorvastatin Placebo in Subjects with Type 2 Diabetes Mellitus - DIO-502. DiObex Inc. 2007 - 2008: $44,320

A Randomized, Double-Blind, Placebo-Controlled Study of XL784 Administered Orally to Subjects with Albuminuria Due to Diabetic Nephropathy - XL784-201. Exelixis, Inc. 2007 - 2008: $53,772

A Pivotal, Open-Label, Parallel Study to Evaluate the Safety and Efficacy of Human Insulin Inhalation Powder (HIIP) Compared to Injectable Insulin in Patients with Diabetes and COPD or Asthma - protocol H7U-MC-IDAS. Lilly Research Laboratories. 2007 - 2009: $35,086

A Randomized-Withdraw Phase III Study Evaluating the Safety and

Efficacy of CG5503 Extended-Release (ER) in Subjects with Painful Diabetic Peripheral Neuropathy (DPN) - R331333-PAI-3015. Johnson & Johnson Pharmaceutical Research & Development. 2007 - 2008: $31,864

A Multi-Center, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment with Vildagliptin (50 mg qd or 100 mg qd) versus Placebo in Patients with Type 2 Diabetes and Moderate Renal Insufficiency - CLAF237A23137. Novartis Pharmaceuticals. 2007 - 2009: $110,454

A Multi-Center, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment with Vildagliptin (50 mg qd or 100 mg qd) versus Placebo in Patients with Type 2 Diabetes and Severe Renal Insufficiency - CLAF237A 23138. Novartis Pharmaceuticals. 2007 - 2009: $115,896

A Phase 2a, Randomized, Double-Blind, Placebo- And Active-Controlled, Parallel-Group, Multicenter Study to Assess the Safety and Efficacy of ADL5859 100mg BID in Subjects with Neuropathic Pain Associated with Diabetic Peripheral Neuropathy - 33CL231. Adolor Corporation. 2007 - 2008: $60,400

A Phase III Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of MK-0431A in Patients with Type 2 Diabetes Mellitus. Merck: 2007 - 2009: $26,000

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of E2007 in Patients with Painful Diabetic Neuropathy. Eisai: 2007-2009: $57,312

An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin Viaject in Subjects with Type 2 Diabetes Mellitus. Biodel. 2007-2010:

An Open Label Follow-On Study of Safety and Pharmacodynamic Effects of 24 Weeks of Treatment with DIO-902 in Combination with Metformin and Atorvastatin in Subjects with type 2 Diabetes Mellitus (Protocol DIO-503). DiObex: 2007-2008: $27,551

BHT-3021-01: A Randomized, Blinded, Placebo Controlled Safety and Pharmacodynamic Study of BHT-3021 with Open Label Cross-Over in Subjects with Type I Diabetes Mellitus. Bayhill Therapeuticals: 2007-2009: $97,500

Effect of insulin glulisine compared to insulin aspart and insulin lispro when administrated by Continuous Subcutaneous Insulin Infusion (CSII) on specific pump parameters in Type 1 DM (APIDR_C_02083). Sanofi-aventis: 2007-2010: $60,000

1218.20 - A Randomised, Double-Blind, Active-Controlled Parallel Grup Efficacy and Safety Study of BI 1356 (5 mg Administered Orally Once Daily) Compared to Glinepiride (1 to 4 mg Once Daily) Over Two Years in Type 2 Diabetic Patients with Insufficient Glycaemic Control Despite Metformin Therapy. Boehringer Ingelheim: 2007-2010: $42,776

1218.17 - A Randomised, Double-Blind, Placebo-Controlled Parallel Group Efficacy and Safety Study of BI 1356 (5 mg administered orally once daily) over 24 weeks in type 2 diabetic patients with insufficient glycaemic control despite metformin therapy. Boehringer Ingelheim: 2007-2008: $36,155

Abbott M10-815 – A Phase 2a, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Safety and Efficacy of Atrasentan on Reducing Albuminuria in type 2 Diabetic nephropathy Subjects who are Currently Being Treated with an Renin-Angiotensin System Inhibitor. Abbott Laboratories: 2009 – 2010: $19,502

Abbott M05-741 VITAL Study – Selective VITamin D Receptor Activator (Paricalcitol) for Albuminuria Lowering Study: A Phase 2, Prospective, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the safety and Efficacy of Paricalcitol Capsules on Reducing Albuminuria in Type 2 Diabetic Nephropathy Subjects who are Currently Being Treated with Renin-angiotensin System Inhibitors. Abbott Laboratories: 2008 – 2010:

Abbott M10-667: An 8 week, Multicenter, randomized, Double-blind, Four-arm, Parallel-group Study Comparing the Safety and Efficacy of ABT-143 to Simvastatin in Subjects with Hypercholesterolemia. Abbott laboratories: 2008 – 2010: $59,981

A Comparison of Diversity of Care in Type 1 Diabetes in African American Compared to European American Children with Diabetes. 2010 – 2014: Unfunded

A Multicenter, randomized, Double-Blind, parallel-Group Study Comparing the Efficacy and Safety of 0.1% Topical Clonidine Gel with Placebo in the Treatment of painful Diabetic Neuropathy. Arcion Therapeutics, Inc.: 2009- 2010: $42, 781

1218.36 – A Phase III randomized, double-blind, placebo-controlled, parallel group efficacy and safety study of Linagliptin (5 mg), administered orally once daily for at least 52 weeks in type 2 diabetic patients in combination with basal insulin therapy. Boehringer Ingelheim International GmbH: 2010 – 2014: $47,185

1245.25 – A Phase III, multicentre, international, randomized, parallel group, double blind cardiovascular safety study of BI 10773 (10 mg and 25 mg administered orally once daily) compared to usual care in type 2 diabetes mellitus patients with increased cardiovascular risk. Boehringer Ingelheim International GmbH: 2010 – 2014: $50,500

1245.28 – A phase III randomized, double-blind, active-controlled parallel group efficacy and safety study of BI 10773 compared to glimepiride administered orally during 104 weeks in patients with type 2 diabetes mellitus and insufficient glycaemic control despite metformin treatment. Boehringer Ingelheim International GmbH: 2010 – 2014: $49,896

1245.33 – A phase IIb, randomized, double-blind, placebo-

controlled, parallel group, safety and efficacy study of BI 10773 (10 mg and 25 mg) administered orally, once daily over 78 weeks in type 2 diabetic patients receiving treatment with basal insulin (glargine, detemir, or NPH insulin only) with or without concomitant metformin and/or sulfonylurea therapy and insufficient glycaemic control. Boehringer Ingelheim International GmbH: 2010 – 2014: $46,525

A Phase III, 3-Arm, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Investigate the Impact of Diamyd on the Progression of Diabetes in Patients Newly Diagnosed with Type 1 Diabetes Mellitus. Diamyd Therapeutics: 2009 – 2013: $37,850

A Multi-Center, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of E2007 (Perampanel) in Patients with Painful Diabetic Neuropathy (PDN) or Post-Herpetic Neuralgia (PHN) – E2007-G000-228: Eisai Medical Research, Inc.: 2009 – 2010:

GLP114130 – A Randomized, Double-Glind, Active-Controlled, parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide as Compared with Sitagliptin in Subjects with Type 2 Diabetes Mellitus with Renal Impairment. GlaxoSmithKline: 2010 – 2014: $57,600

GLP114179 – A Randomized, open-Label, Parallel-Group, Multicenter Study to Determine the efficacy and Safety of Albiglutide as Compared With Liraglutide in Subjects With Type 2 Diabetes Mellitus. GlaxoSmithKline: 2010 – 2014: $39,050

GLP108486 – A Randomized, Open-Label, Active-Controlled, Parallel-Group, Multicenter Study to Determine the Safety and Efficacy of Albiglutide Administered in Combination With Insulin Glargine as Compared with the Combination of Insulin Glargine and Preprandial Lispro Insulin in Subjects With Type 2 Diabetes Mellitus. GlaxoSmithKline: 2010 – 2014: $52,745

RAO112438 – A randomized, single-blind, placebo-controlled, study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of single ascending and repeat dose administration of otelixizumab in subjects with Type 1 Diabetes Mellitus. GlaxoSmithKline: 2011 – 2015:

GLP112753 – A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the efficacy and Safety of Albiglutide When Used in Combination With Metformin Compared With Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects With Type 2 Diabetes Mellitus. GlaxoSmithKline: 2010 – 2014: $137,149

GLP112754 – A Randomized, Open-Label, Parallel-Group, Multicener Study to Determine the Efficacy and Long-Term Safety of Albiglutide Compared With Insulin in Subjects With type 2 Diabetes Mellitus. GlaxoSmithKline: 2010 – 2014: $75,581

GLP112755 – A Randomized, Double-Blind, Placebo-Controlled,

Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination With Pioglitazone With or Without Metformin in Subjects with Type 2 Diabetes Mellitus. GlaxoSmithKline: 2010 – 2014: $69,437

GLP112756 – A Randomized, Double-Blind,Placebo-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Two Dose Levels of Albiglutide Compared With Placebo in Subjects With Type 2 Diabetes Mellitus. GlaxoSmithKline: 2010 – 2014: $79,516

GLP112757 – A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepiride Compared With Metformin Plus Glimepiride and Placebo and With Metformin Plus Glimepiride and Pioglitazone in Subjects With Type 2 Diabetes Mellitus. GlaxoSmithKline: 2010 – 2014: $76,260

ITN045AI - Inducing Remission in New Onset T1DM with Alefacept (Amevive). Immune Tolerance Network: 2010 – 2014: $173,449

H9V-MC-GFRF – A Randomized, Double-Masked, Placebo-Controlled, Multicenter, phase 2 Study to Evaluate the Safety and Renal Efficacy of LY2382770 in Patients with Diabetic Kidney Disease due to Type 1 or Type 2 Diabetes. Eli Lilly and Company: 2010 – 2014: $84,394

F3Z-MC-IOQC – Two Approaches to Escalate Lispro Therapy in Patients with Type 2 Diabetes Mellitus Not Achieving Adquate Glycemic Control on Basal Insulin Therapy and Oral Agents Alone. Eli Lilly and Company: 2010: $114,201

CP-MGA031-01 – A Phase 2/3, Randomized, Double-Blind, Multicenter, multinational, 4-Arm, Controlled, Dose-Ranging Study to Evaluate Efficacy and Safety of MGA031, a Humanized, FcR Non-Binding, Anti-CD3 Monoclonal Antibody, In Children and Adults with Recent-Onset Type 1 Diabetes Mellitus. MacroGenics, Inc.: 2006 – 2011: $197,796

CP-MGA03-02 – A Multicenter, multinational Extension of Study CP-MGA031-01 to evaluate the Long-Term Efficacy and Safety of Teplizumab (MGA031), A Humanized FcR Non-Binding, Anti-CD3 Monoclonal Antibody, in Chilcren and Adults with Recent-Onset Type 1 Diabetes Mellitus. MacroGenics, Inc.: 2010 – 2011: $65,852

A Phase 3, 24-Week, Multi-Center, Open-Label, Randomized, Controlled Trial Comparing the Efficacy and Safety of Prandial inhalation of Technosphere / Insulin in Combination with metformin or Technosphere / Insulin Alone Versus 2 Oral Anti-Diabetic Agents (Metformin and Secratagogue) in Subjects with Type 2 Diabetes Mellitus Sub-Optimally Controlled on Combination Metformin and a Secretagogue. MannKind Corporation:

A Prospective, Multi-Center, open-Label, randomized, Controlled clinical trial Comparing the Efficacy and Safety in Subjects with Type 1

Diabetes receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere / Insulin Versus Subcutaneous Basal and Prandial Insulin Over a 52-Week Treatment Period and a 4-Week Follow-Up. MannKind Corporation:

A Prospective, Multi-Center, Open-Label, Randomized, Controlled Study Comparing the Efficacy and Safety in Subjects with Type 2 Efficacy and Safety in Subjects with Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere / Insulin Versus Subcutaneous Premixed Insulin therapy Over a 52-Week Treatment Period and a 24-Week Follow-Up. MannKind Corporation:

MKC-TI-161 – A Phase 3b, Multicenter, Open-label, Randomized, Forced-titration Clinical Trial Evaluating the Efficacy and Safety of Technosphere Insulin inhalation Powder, Using the Gen2 Inhaler, in Combination with Insulin glargine Versus Insulin Aspart in Combination with Insulin Glargine in Subjects with Type 1 Diabetes Mellitus Over a 16-week Treatment Period. MannKind Corporation: 2010 – 2014: $54,048

MKC-TI-162 – A Phase 3b, Multicenter, open-label, Randomized, Forced-titration Clinical Trial Evaluating the Efficacy and Safety of Technosphere Insulin Inhalation Powder, Using the Gen2 Inhaler, in Combination with Insulin Glargine Versus Insulin Aspart in Combination with Insulin Glargine in Subjects with Type 2 Diabetes mellitus Over a 16-week Treatment Period. MannKind Corporation: 2010 – 2014: $52, 900

CLAF237A23138E1 – A 28 Week Extension to a 24 Week Multi-Center, Randomized, Double-Blind, Active-Controlled Clinical Trial to Evaluate the Safety and Tolerability of Vildagliptin 50 mg QD versus Sitagliptin 25 mg QD in Patients with Type 2 Diabetes and Severe Renal Insufficiency. Novartis Pharmaceuticals: 2008 – 2012: $21,500.22

NN5401-3594 – A 26-Week, Multinational, Multi-Centre, Open-Labeled, Two-Arm, Parallel, Randomized, Treat-to-Target Trial Comparing Efficacy and Safety of Soluble Insulin Analogue Combination (SIAC) Once Daily Plus Meal-Time Insulin Aspart for the Remaining Meals Vs. B asal-Bolus Treatment with Insulin Detemir Plus Meal-Time Insulin Aspart in Subjects with Type 1 Diabetes. NovoNordisk: 2009 – 2013: $115,307

A0081242 – A Phase 3B Multicenter, Double-Blind, Randomized Withdrawal Efficacy and Safety Study of Pregabalin in the Treatment of Patients with Inadequately Treated Painful Diabetic Peripheral Neuropathy. Pfizer: 2011 – 2015: $33,887.52

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase 2B Study to Evaluate the Safety and Efficacy of Pyridorin (Pyridoxamine Dihydrochloride) in patients with Nephropathy Due to Type 2 Diabetes. Nephrogenix: 2008 – 2011: $38,018

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Assess the Effects of Taspoglutide (RO5073031) on Cardiovascular Outcomes in Subjects with Inadequately Controlled Type 2 Diabetes and Established Cardiovascular Disease. Roche: 2009 – 2011: $230, 753

SB-590-0601: A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects with Diabetic Neuropathy. Sangamo BioSciences, Inc.: 2006 – 2008: $146,900

SB-509-0701 – A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects with Moderate to Severe Diabetic Neuropathy and Unmeasureable Nerve Conduction Velocity. Sangamo BioSciences, Inc.: 2008 – 2009: $87,852

The Effect of Vascular Endothelial Growth Factor Activator Plasmid on Skin Blood Flow and Wound Healing in the Rat. Sangamo BioSciences, Inc.: 2007 – 2009: $72,303

SB-509-0801 - Long-term Follow-up of Subjects Treated with or Exposed to SB-509 Plasmid Gene Therapy. 2009 – 2013: $13,974

SB-509-0901 – A Phase 2b Repeat Dosing Clinical Trial of SB-509 in Subjects with Moderately Severe Diabetic Neuropathy. Sangamo BioSciences, Inc.: 2010 – 2015: $192,904

EFC11319 – A randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate cardiovascular outcomes during treatment with lixisenatide in type 2 diabetic patients after an Acute Coronary Syndrome. Sanofi-aventis U.S. Inc.: 2010 – 2014: $91,292

A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Cotnrolled Study of S-707106 in Subjects with type 2 Diabetes mellitus and Inadequate Glycemic Control with Metformin Therapy. Shionogi USA, Inc.: 2010 – 2014: $39,470

SYR-322_402 – A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment with Alogliptin in Addition to Standard of Care in Subjects with Type 2 Diabetes and Acute Coronary Syndrome. Takeda Global Research & Development Center, Inc.: 2009 – 2013: $68,844

SYR-322-OLE-012 – A Long-Term, Open-Label Extension Study to Investigate the Long-Term Safety of SYR110322 (SYR-322) in Subjects with Type 2 Diabetes. Takeda Global Research & Development Center, Inc.: 2005 – 20012: $458,652.72

SYR-322-SULF-007 – A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and safety of SYR110322 (SYR-322) When Used in Combination with insulin in Subjects with Type 2 Diabetes. Takeda Global Research & Development Center, Inc.: 2005 – 2007: $36,460

SYR-322-MET-008 – A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with Metformin in Subjects with Type 2 Diabetes. Takeda Global Research & Development Center, Inc.: 2005 – 2007: $36,460

SYR-322-PLC-009 – A Multicenter, Randomized, Double-Blind,

Placebo-Controlled Study to Determine the Efficacy and safety of SYR110322 (SYR-322) Compared to placebo in Subjects with Type 2 Diabetes. Takeda Global Research & Development Center, Inc.: 2005 – 2007: $36, 460

SYR-322-INS-011 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination with Insulin in Subjects with Type 2 Diabetes. Takeda Global Research & Development Center, Inc.: 2005 – 2007: $36,460

SYR-322-TZD-010 – A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110332 (SYR-322) When Used in Combination with Pioglitazone in Subjects with Type 2 Diabetes. Takeda Global Research & Development Center, Inc.: 2005 – 2007: $36,460

TAK-875_201 – A Phase 2, Randomized, Double-Blind, Double-Dummy, Placebo- and Active-Controlled, multicenter Study to Determine the Efficacy and Safety of TAK-875 in Subjects with Type 2 Diabetes Mellitus. Takeda Global Research & Development Center, Inc.: 2009 – 2011: $51,845

TECOS: A Randomized, placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control – Protocol 082-01. Merck & Co., Inc.: 2010 – 2014: $43,073

TRX4_DM_006_NA_08 – DEFEND-1: Durable-Response Therapy Evaluation for Early- or New-Onset Type 1 Diabetes. Tolerx, Inc.: 2008 – 2012: $155,826

TRX4_DM_008_WW_10 – DEFEND-1 Long Term Follow Up: Durable-Response Therapy Evaluation for Early or New Onset Type 1 Diabetes Extension Study. Tolerx, Inc.: 2010 – 2016: $45,375

RAO112438 – A Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerabiltiy, Pharmacodynamics and Pharmacokinetics of Single Ascending and Repeat Dose Administration of Otelixizumab in Subjects with Type 1 Diabetes Mellitus. GlaxoSmithKline: 2011 – 2015: $410,075

TRX4_DM-005_NA-06 – TRX4 Therapeutic Evaluation of Different Multi-Dose Regimens in Type 1 Diabetes Mellitus (TTEDD). Tolerx, Inc.: 2009 – 2011: $217,876

TREAT - Trial to Reduce Cardiovascular Events with Aranesp. Amgen. 2004 – 2010: $205,000

DVS SR 3151A5-322-US – A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 13 Week, Adaptive-Design Study of 4 Fixed Oral Doses of DVS SR in Adult Outpatients with pain Associated with Diabetic Peripheral Neuropathy. Wyeth Pharmaceuticals. 2006 – 2009: $75,000

DVS SR 3151A5-325-US – A 9-Month Open-Label extension Study of the Long-Term Safety of DVS SR in Outpatients with pain Associated with Diabtic Peripheral Neuropathy. Wyeth Pharmaceuticals. 2006 – 2010: $63,375

Abbott 05-750 – A Multicenter, Randomized, Double-Blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Atorvastatin Calcium Combination Therapy to Fenofibric Acid and Atorvastatin Calcium Monotherapy in Subjects with Mixed Dyslipidemia. Abbott Pharmaceuticals. 2005 – 2007: $31,425

Abbott M05-758 – A Long-Term, Open-Label, Safety Extension Study of the Combination of Fenofibric Acid and Statin Therapy for Subjects with Mixed Dysplipidemia. Abbott Pharmaceuticals. 2006 – 2007: $31,070

Abbott M11-350 – RADAR: Reducing Residual Albuminuria in Subjects with Diabetes and Nephropathy with AtRasentan – A Phase 2b, Prospective, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate Safety and Efficacy. Abbott Pharmaceuticals. 2011 – 2015: $217,087.50

Abbott M11-891: A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-639 to Placebo in Subjects with Diabetic Neuropathic Pain. Abbott Pharmaceuticals. 2011 – 2015: $144,305

Abbott M05-850 – A Multicenter, Randomized, Double-Blind, Placebo-controlled, parallel Study Comparing the Analgesic Efficacy and the Safety of ABT-894 (1 mg, 2mg, and 4 mg), Duloxetine (60 mg) and Placebo in Approximately 275 Subjects with Diabetic Neuropathic Pain. Abbott Pharmaceuticals. 2008 – 2012: $97,521

A Multi-Center, Double-Blind, Randomized, placebo-Controlled, multiple Dose, parallel Design, Dose Ranging Study of the Safety and Efficacy of AGN203818 in Patients with painful Diabetic Peripheral Neuropathy. Allergan. 2006 – 2010: $144,250

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Adding Symlin to Lantus (Insulin Glargine) in Subjects with Type 2 Diabetes Who Are Not Achieving Glycemic Targets. Amylin. 2005 – 2009: $26,300

APIDRA (ingulin glulisine) administered premeal vs. postmeal in adult subjects with type 2 Diabetes Mellitus receiving LANTUS (insulin glargine) as basal insulin – a multicenter, randomized parallel, open label clinical study. Aventis Pharmaceuticals. 2004 – 2008: $68,000.

One Versus Two Versus Three Daily Rapid-Acting Insulin Injections of Apidra (Insulin Glulisine) as Add-On to Lantus and Oral Sensitizer Basal Therapy in Type 2 Diabetes: A Multi-Center, Randomized, Parallel, Open-Label Clinical Study. Aventis Pharmaceuticals. 2005 – 2009: $115,000

A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, phase 2 Study Designed to Assess the Efficacy and Safety of FK1706 in Subjects with Painful Diabetic Neuropathy. Astellas Pharmaceuticals. 2005 – 2009: $33,800

Evaluation of the Effect of Transdermal Testosterone Supplementation on Glycemic Control, Body Composition, and Lipid Concentrations in Hypogonadal Men with non-Insulin-Dependent Diabetes Mellitus. Auxilium: 2005 – 2009: $20,000

A Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Dextromethorphan and Quinidine at Two Dose Levels in the Treatment of the Pain of Diabetic Neuropathy. Avanir: 2005 – 2008:

A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-652 to Placebo in Subjects with Diabetic Neuropathic Pain. Abbott 210. 2012. $231,825

A Randomized, Double-Blind, Placebo and Active Comparator-Controlled Study of DS-5565 For Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy. Daiichi Sankyo. 2011 - 2012. $46,000

A Multidose Study in Subjects with Type 2 Diabetes Mellitus to Assess the Pharmacokinetics and Pharmacodynamics of Albiglutide - GSK GLP114856. GSK. 2011-2013. $62,495

ITCA 650-CLP-103 sub-study – An Open-Label Multi-center Sub-Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients with Type 2 Diabetes with Higher Baseline HbA1c. Intarcia. 2013. $2,500

Skin Blood Flow in Patients with Type 1 Diabetes Mellitus Compared to Normal Controls. Unfunded. 2012.

The Effect of Insulin Pump Therapy on Skin Blood Flow. Unfunded. 2003 - 2010

A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Co-Administration of Sitagliptin and Atorvastatin in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin Monotherapy - Protocol number MK-0431E-211. Merck. 2012. $38,723

A Phase 3b, Multicenter, Randomized, Single-blind, Parallel Group Trial of the Effects of Titrated Oral SAMSCA (Tolvaptan) 15, 30, or 60 mg QD Compared to Placebo Plus Fluid Restriction on Length of Hospital Stay and Symptoms in Subjects Hospitalized with Dilutional Hyponatremia. Otsuka. 2012. $69,263

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Efficacy, Safety and Tolerability of SKL11197 for the Pain of Diabetic Peripheral Neuropathy. SKL. 2011-

2013. $52,124.

A Randomized, Double-Blind, Phase 3b Proof-of-Concept Study to Evaluate the Efficacy and Safety of TAK-491 Compared to Placebo When Used in Combination With Metformin in Subjects with Hypertension and Type 2 Diabetes. Takeda. 2012-2013. $516,240.

A Phase 2B, randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of CBX129801 (Ersatta), Long-acting Synthetic C-Peptide, in Type 1 Diabetes Mellitus Subjects with Mild to Moderate Diabetic Peripheral Neuropathy. Cebix. 2012-2014. $44,496

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of ITCA 650 in Patients with Type 2 Diabetes - ITCA 650-CLP-103. Intarcia. 2012-2013. $39,212.

A Randomized, Multicenter Study to Evaluate Cardiovascular Outcomes with ITCA 650 in Patients Treated with Standard of Care for Type 2 Diabetes – ITCA 650-CLP-107. Intarcia. 2013-2016. $95,561.

A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide with Insulin Glargine on Glycemic Control in Patients with Type 2 Diabetes and Moderate or Severe Chronic Kidney Disease," protocol H9X-MC-GBDX. Lilly. 2012-2016. $79,309.

A Phase III, Randomized, Double-Blind, Clinical Trial to Study the Efficacy and Safety of MK-0431D (a fixed-dose combination [FDC] of sitagliptin and simvastatin) for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM) with Inadequate Glycemic Control on Metformin Monotherapy 266-00. Merck. 2012-2013. $112,855.

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus" OMNEON™-18. Merck. 2012-2016. $512,473.

A Phase 3, Multicenter, Open-label, Randomized, Forced-titration Clinical Trial Evaluating the Efficacy and Safety of Technosphere® Insulin Inhalation Powder in Combination with a Basal Insulin Versus Insulin Aspart in Combination with a Basal Insulin in Subjects with Type 1 Diabetes Mellitus Over a 24-week Treatment Period" ("Study") in accordance with MannKind's Protocol no. MKC-TI-171. MannKind Corporation. 2011-2013. $59,550.

A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized, Clinical Trial Evaluating the Efficacy and Safety of Prandial Technosphere® Insulin Inhalation Powder Versus Technosphere® Inhalation Powder (Placebo) in Insulin Naïve Subjects with Type 2 Diabetes Mellitus Poorly Controlled with Oral Antidiabetic Agents Over a 24-week Treatment Period" ("Study") in accordance with MannKind's Protocol no. MKC-TI-175. MannKind Corporation. 2012-2013. $48,475.

A Phase 2, Randomized, Double-blind, Placebo-Controlled, Parallel

Group, Multi-Center Study to Evaluate the Efficacy and Safety of Once-Daily Administration of a Chemokine CCR2/5 Receptor Antagonist (PF-04634817) in Adults with Type 2 Diabetes and Overt Nephropathy. Pfizer. 2012-2016. $28,930.

6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients with Type 2 Diabetes Mellitus not Adequately Controlled with Non-Insulin Antihyperglycemic Drugs with a 6-month Safety -Protocol 12347. Sanofi-aventis. 2012 – 2016. $72,859.

A 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® Injected in the Morning or Evening in Patients with Type 1 Diabetes Mellitus with a 6-month Safety Extension Period - protocol 12356. Sanofi-aventis. 2012-2016. $70,066.

A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 mg and 50 mg Compared with Placebo in Subjects with Type 2 Diabetes", TAK-875_301. Takeda Pharmaceuticals. 2011-2013. $232,555.

A Multicenter, Randomized, Double-Blind, Active-Cotnrolled, phase 3 Study to evaluate the Efficacy and Safety of TAK-875 25 mg and 50 mg Compared to Glimepiride When Used in Combination with Metformin in Subjects with Type 2 Diabetes – TAK-875_304. Takeda Pharmaceuticals. 2012-2016. $74,848.

TrialNet Natural History Study of the Development of Type 1 Diabetes. TrialNet. 2012-2016. $4,420.

(M11-352) SONAR: Study of Diabetic Nephropathy with Atrasentan - Randomised, Multicountry, Multicenter, Double Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy. Abbott Laboratories. 2013-2017. $120,350.

A Double-Blind, Randomized, Placebo-Controlled, Phase 2 Study Evaluating the Safety and Efficacy of Oral GKT137831 in Patients with Type 2 Diabetes and Albuminuria- protocol GSN000200. Genkyotex. 2013-2017. $45,995.

A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Safety and Efficacy of LX4211 in Patients with Inadequately Controlled Type 1 Diabetes Mellitus – protocol LX4211.1-203-T1DM. 2013-2017. $56,525.

A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus in Subjects With Type 1 Diabetes Mellitus MK-1293-003-014. Merck. 2013-2017. $140,406.

A Phase III Clinical Trial to Study the Safety and Efficacy of MK-1293 Compared to Lantus in Subjects with Type 2 Diabetes Mellitus" 1293-006/. Merck. 2013-2017. $254,352.

A Phase 3, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Safety of Technosphere Insulin Inhalation Powder in Type 1 or Type 2 Diabetic Subjects With Obstructive Pulmonary Disease (Asthma or Chronic Obstructive Pulmonary Disease) Over a 12- Month Treatment Period with a 2-Month Follow-up – MKC-TI-134. MannKind Corporation. 2013-2017. $62,836.

A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter, 24-week study assessing the safety and efficacy of lixisenatide in older patients with type 2 diabetes inadequately controlled on their current diabetes treatment regimen- protocol 12703. Sanofi-aventis. 2013-2017. $64,000

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, 24-Week Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 50 mg Compared With Placebo as an Add-On to Glimepiride in Subjects With Type 2 Diabetes", TAK-875_309. Takeda Pharmaceuticals. 2013-2017. $68,728.

PUBLICATIONS

1) Rendell M, Arents J: Gaussian Orbital Approximation for the Hydrogen Atom by Minimization of Variance. **J of Chem Physics** 49: 5366-5368, 1968

2) Rein R, Rendell MS, Harlos JP: Possible Interactions in the Primitive Translation Process. In **Molecular Orbital Studies in Chemical Pharmacology**, editor LB Kier, Springer, New York, 1970

3) Rendell M, Harlos J, Rein R: Specificity in the Genetic Code: The Role of Nucleotide Base-Amino Acid Interaction. **Biopolymers** 10: 2083-2094, 1971

4) Rendell M: A Computer Investigation into the Origin of the Code. **J of Amer Chem Soc** 94: 4337-4341, 1972

5) Rendell M, Soorani J: The Effect of Complex Modifiers on Large Enzyme Systems. **Mathematical Biosciences** 17: 79-88, 1973

6) Rendell M: Stochastic Dose-Response. **Mathematical Biosciences** 19: 307-317, 1974

7) Rodbell M, Lin MC, Salomon Y, Londos C, Harwood JP, Martin BR, Rendell M, Berman

M: The Role of Adenine and Guanine Nucleotides in the Activity and Response of Adenylate Cyclase Systems to Hormones: Evidence for Multi-Site Transition States. **Acta Endocrinologica** 77: 11-37, 1974

8) Salomon Y, Lin MC, Londos C, Rendell M, Rodbell M: The Hepatic Adenylate Cylase System I. Evidence for Transition States and Structural Requirements for Guanine Nucleotide Activation. **J of Biol Chem** 250: 4239-4245, 1975

9) Lin MC, Salomon Y, Rendell M, Rodbell M: The Hepatic Adenylate Cyclase System II. Substrate Binding and Utilization and the Effect of Magnesium Ion and pH. **J of Biol Chem** 250: 4246-4252, 1975

10) Rendell M, Salomon Y, Lin MC, Rodbell M, Berman M: The Hepatic Adenylate Cyclase System III: A Mathematical Model for the Steady State Kinetics of Catalysis and Nucleotide Regulation. **J of Biol Chem** 250: 4253-4260, 1975

11) Rodbell M, Lin MC, Salomon Y, Londos C, Harwood JP, Martin BR, Rendell M, Berman M: The Role of Adenine and Guanine Nucleotides in the Activity and Response of Adenylate Cyclase Systems to Hormones. Evidence for Multi-Site Transition States. In **Advances in Cyclic Nucleotide Research**, Vol 5, edited by GI Drummond, P Greengard, A Robinson, Raven Press, New York, 1975

12) Rendell MS, Rodbell M, Berman M: Activation of Hepatic Adenylate Cyclase by Guanyl Nucleotides. Modeling of the Transient Kinetics Suggests an "Excited" State of GTPase Is a Control Component of the System. **J Biol Chem** 252: 7909-7912, 1977

13) Rendell M, McGrane D, Cuesta M: Fatal Compulsive Water Drinking. **JAMA** 240: 2557-2559, 1978

14) Rendell M, Slevin D, Meltz G, Simpson J, Barquet A: A Case of Maturity Onset Diabetes Mellitus Resistant to Insulin but Responsive to Tolbutamide. **Ann Int Med** 90: 195-197, 1979

15) Rendell M: Letter to the Editor: C-Peptide Assay. **Ann Int Med** 91: 131, 1979

16) Schmidt MI, Hadji-Georgopoulos A, Rendell M, Margolis S, Kowarski D, Kowarski AA: Hyperglycemia and Associated Free Insulin and Cortisol Changes in "Somogyi"-Like Patients During Continuous Glucose Monitoring. **Diabetes Care** 2: 457-464, 1979

17) Rendell M, Drew HM, Nickoloff E: C-Peptide as a Clinical Assay. **The Ligand Quarterly** 2: 20-23, 1979

18) Brown M, Salmon D, Rendell M: Clonidine Hallucinations. **Ann Int Med** 96: 1022-1036, 1980

19) Hamilton RG, Rendell M, Adkinson NF Jr: Serological Analysis of Human IgG and IgE Anti-Insulin Antibodies Using Solid Phase Radioimmunoassays. **J Lab Clin Med** 96: 1022-1036, 1980

20) Rendell M, Drew HM, Hamilton RG, Adkinson NF Jr: Exacerbation of Diabetes Mellitus by Antibodies Induced by Exogenous Insulin. **Am J Med Sci** 282: 18-26, 1981

21) Rendell M, Zarriello J, Drew HM, Dranbauer B, Wilson G, Waud J, Ross DA: Recovery From Decompensated Maturity Onset Diabetes Mellitus: Studies of C-Peptide Secretion. **Diabetes Care** 4: 354-359, 1981

22) Renie A, Hamilton RG, Adkinson NF Jr, Rendell MS: A Case of Hyperlabile Diabetes Accompanied by Insulin Resistance. **Clin Chem** 27: 1463-1464, 1981

23) Pincus M, DeLisi C, Rendell M: Ligand Binding to a Linear Resin Chain with Excluded Volume Effects. **Biochimica Biophysica Acta** 675: 392-396, 1981

24) Schmidt MI, Hadji-Georgopoulos A, Rendell M, Margolis S, Kowarski A: The Dawn Phenomenon, An Early Morning Glucose Rise. Implications for Diabetic Intraday Blood Glucose Variation. **Diabetes Care** 4: 579-585, 1981

25) Rendell M, Ross DA, Drew HM, Zarriello J: Endogenous Insulin Secretion Measured by C-Peptide in Maturity Onset Diabetes Controllable by Diet Alone. **Arch Int Med** 141: 1617-1622, 1981

26) Pincus MR, Rendell M: General Quantitative Treatment for the Binding of Divalent Antibodies to Antigens Immobilized on a Solid Phase. **Proc Nat Acad Sci, USA** 78: 5924-5927, 1981

27) Salmon D, Rendell M, Williams J, Smith C, Ross DA, Waud J, Howard JE: Chemical Hyperthyroidism. **Arch Int Med** 142: 571-573, 1982

28) Meistas MT, Rendell M, Margolis ST, Kowarski AA: Estimation of the Secretion Rate of Insulin from the Urinary Excretion Rate of C-Peptide: Study in Obese and Diabetic Subjects. **Diabetes** 31: 449-453, 1982

29) Lassek WD, Rendell M, Ross DA, Smith C, Kernek S, Williams J, Brown M, Willingmyre L, Yamamoto L: Epidemiologic and Clinical Use of Pharmaceutical Profiles in an Ambulatory Care Data System in **Proceedings of the Sixth Annual Symposium on Computer Applications in Medical Care**, edited by BI Blum, Computer Society Press, IEEE Computer Society, Los Angeles, 1982

30) Rendell M, Ross DA, Lassek WD, Kernek S, Williams J, Smith C, Brown M, Willingmyre L, Yamamoto L: A Pharmaceutical Profile of Diabetic Patients. **J Chron Dis** 36: 193-202, 1983

31) Rendell M: Reversibility of Insulin Dependence in Diabetes. **Practical Cardiology** 9: 145-151, 1983

32) Rendell M: Misuse of Laboratory Tests and Diagnostic Procedures. Letter to the Editor: **New Engl J Med** 308: 1035-1036, 1983

33) Rendell M: The Expanding Clinical Usefulness of the C-Peptide Radioimmunoassay. **Acta Diabetol Latina** 20: 105-113, 1983

34) Rendell M: C-Peptide Levels as a Criterion in Treatment of Maturity Onset Diabetes. **J Clin Endo Metab** 57: 1198-1206, 1983

35) Rendell M: The Clinical Laboratory and Diabetes. Part I: C-Peptide. **Pathology Update Series**. Vol. I, Lesson 20, pgs 1-7, 1984

36) Rendell M, Kao G, Mecherikunnel P, Petersen B, Duhaney R, Nierenberg J, Rasbold K, Klenk D, Smith PK: The Use of Aminophenylboronic Acid Affinity Chromatography to Measure Glycosylated Albumin. **J Lab Clin Med** 105: 63-69, 1985

37) M Rendell, G Kao, P Mecherikunnel, B Petersen, R Duhaney, J Nierenberg, K Rasbold, D Klenk, PK Smith: Aminophenylboronic Acid Affinity Chromatography and Thiobarbituric Acid Colorimetry Compared for Measuring Glycated Albumin. **Clin Chem** 31: 229-234, 1985

38) MS Rendell: **Disorders of Glucose Metabolism. A Guide to the Use of C-Peptide and Insulin Measurements**. Monograph published and distributed by the Immunonuclear Corporation, Stillwater, Minnesota, 1984

39) Rasbold K, Rendell MS, Goljan E: Simple Removal of Lipids from Serum. **Clin Chem** 31:782, 1985

40) JL Valentine, PM Stephen, M Rendell, R Paulsen, D Shin, S Eastberg, C Smith: Noninsulin Dependent Alloxan Induced Diabetes Mellitus in the Rabbit. **Lab Animal** 4: 39-42, 1985

41) M Rendell, D Salmon:"Chemical Hyperthyroidism": The Significance of Elevated Serum Thyroxine Levels in L-Thyroxine Treated Individuals. **Clin Endocrinol** 22: 693-700, 1985

42) M Rendell, PM Stephen, R Paulsen, JL Valentine, K Rasbold, T Hestorff, S Eastberg: An Interspecies Comparison of Normal Levels of Glycohemoglobin and Glycoalbumin. **Comp Biochem & Physiol** 81B: 819-822, 1985

43) M Rendell, R Paulsen, S Eastberg, PM Stephen, JL Valentine, CH Smith, J Nierenberg, K

Rasbold, D Klenk, PK Smith: Clinical use and time relationship of changes in glycosylated albumin and glycosylated hemoglobin measured by affinity chromatography. **Amer J Med Sci** 292: 11-14, 1986

44) M Rendell, K Rasbold, J Nierenberg, R Krohn, G Hermanson, D Klenk, PK Smith: Comparison and Contrast of Affinity Chromatographic Determination of Plasma Glycated Albumin and Total Glycated Plasma Protein. **Clin Biochem** 19: 216-220, 1986

45) M Rendell, S Dodds, LP Mercer, PM Stephen, JL Valentine, K Rasbold, J Nierenberg, PK Smith: Decreased Glycoalbumin Levels Induced by Aspirin Treatment in the Rat. **J Lab Clin Med** 108: 286-293, 1986

46) JJ Katims, EH Naviasky, LKY Ng, M Rendell, ML Bleecker: A New Screening Device for the Assessment of Peripheral Neuropathy. **J Occup Med** 28: 1219-1221, 1986

47) JJ Katims, EH Naviasky, M Rendell, ML Bleecker: Constant Current Sine Wave Transcutaneous Nerve Stimulation for the Evaluation of Peripheral Neuropathy. **Arch Phys Med Rehabil** 68: 210-213, 1987

48) M Rendell, C Brannan, J Nierenberg, K Rasbold, T Hestorff, D Klenk, PK Smith: Fingerstick Glycated Hemoglobin and Glycated Albumin. **Diabetes Care** 10: 629-632, 1987

49) ER Evans, MS Rendell, A Schueneman, F Hamilton, J Calvert: Gestational Diabetes. **Amer Fam Physician** 36(6): 119-126, 1987

50) MS Rendell, JJ Katims, R Richter, F Rowland: A Comparison of Nerve Conduction Velocities and Current Perception Thresholds as Correlates of Clinical Severity of Diabetic Sensory Neuropathy. **J Neurol Neurosurg Psych** 52: 502- 511, 1989

51) M Rendell, T Bergman, G O'Donnell, E Drobny, J Borgos, RF Bonner: Microvascular Blood Flow, Volume, and Velocity Measured by Laser Doppler Techniques in Insulin Dependent Diabetes. **Diabetes** 38: 819-824, 1989

52) MS Rendell, DJ Dovgan, TF Bergman, GP O'Donnell, EP Drobny, JJ Katims: Mapping Diabetic Sensory Neuropathy by Current Perception Threshold Testing. **Diabetes Care** 12: 636-640, 1989

53) WR Kirchain, MS Rendell: Aldose reductase inhibitors. **Pharmacotherapy** 10: 326-336, 1990

54) Rendell M, Fox M, Knox S, Lastovica J, Kirchain W, Meiselman HJ: The effects of glycemic control on red cell deformability determined using the cell transit time analyzer (CTTA). **J Lab Clin Med** 117: 500-504, 1991

55) Katims JJ, Patil AS, Rendell M, Rouvelas P, Sadler B, Weseley SA, Bleecker ML: Current perception threshold screening for carpal tunnel syndrome. **Archives of Environmental**

Health 46: 207-212, 1991

56) Rendell MS, Giitter M, Bamisedun O, Davenport K, Schultz R: The laser Doppler analysis of posturally induced changes in skin blood flow at elevated temperatures **Clin Physiol** 12: 1-13, 1992

57) Rendell M, Luu T, Quinlan E, Knox S, Fox S, Kelly S, Koehler K: Red cell filterability determined using the Cell Transit Time Analyzer (CTTA): Effects of ATP depletion and changes in calcium concentration. **Biochim Biophys Acta** 1133: 293-300, 1992

58) Rendell M as part of the Consensus Development Group: Proceedings of a Consensus Development Conference on Standardized Measures in Diabetic Neuropathy. **Diab Care** 15 (Suppl 3): 1080-1107, 1992

59) Rendell M, Bamisedun O: Skin blood flow and current perception in pentoxifylline treated diabetic neuropathy. **Angiology** 43: 843-851, 1992

60) Evans ER, Rendell MS, Bartek JP, Bamisedun O, Connor S, Giitter M: Current perception thresholds in aging. **Age & Ageing** 21: 273-279, 1992

61) Rendell M, Bamisedun O: Diabetic cutaneous microangiopathy. **Amer J Med** 93: 611-618, 1992

62) Evans E, Rendell M, Bartek J, Connor S, Bamisedun O, Dovgan D, Giitter M: Thermally induced cutaneous vasodilatation in aging. **J Gerontol: Med Sci** 48: M53-M57, 1993

63) Rendell MS, Kelly ST, Bamisedun O, Luu T, Finney DA, Knox S: The effect of increasing temperature on skin blood flow and red cell deformability. **Clin Physiol** 13: 235-245, 1993

64) Rendell MS, McIntyre SF, Terando JV, Kelly ST, Finney DA: Skin blood flow in the Wistar-Kyoto rat and the Spontaneously Hypertensive rat. **Comp Biochem & Physiol** 106A: 349-354, 1993

65) Rendell M, Kimmel DB, Bamisedun O, O'Donnell ET, Fulmer J: The health care status of the diabetic population as reflected by physician claims to a major insuror. **Arch Int Med** 153: 1360-1366, 1993

66) Rendell MS, Kelly ST, Finney D, Luu T, Kahler K, McIntyre SF, Ternado JV: Decreased skin blood flow early in the course of streptozotocin-induced diabetes mellitus in the rat. **Diabetologia** 36: 907-911, 1993

67) Rendell M, Milliken BK, McIntyre SF, Satterlee M, Eckermann AJ: The effect of aging on skin blood flow in the Wistar-Kyoto rat. **Comp Biochem Physiol A** 111A: 511-518, 1995

68) Rendell MS, McIntyre SF, Terando JV, Kelly ST, Finney DA, Milliken BK, Kingsley DW, Satterleee M: The effect of polycythemia on skin blood flow in hypertensive rats. **Comp Biochem Physiol A** 112A: 355-363, 1995

69) Rendell MS, Milliken BK, Banset EJ, Finnegan M, Stanosheck C, Terando JV: The effect of chronic hypertension on skin blood flow. **J Hypertens** 14: 609-614, 1996

70) Rendell M. Measurement of cutaneous perception in diabetic neuropathy. Muscle Nerve. 1996 Mar;19(3):406-7 :

71) Kelley DE, Bidot P, Freedman Z, Haag B, Podlecki D, Rendell M, Schimel D, Weiss S, Taylor T, Krol A, Magner J: Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care. 1998 Dec;21(12):2056-61.

72) Rendell MS, Shehan MA, Kahler K, Bailey KL, Eckermann AJ: The effect of calcium channel blockade on skin blood flow in diabetic hypertension: A comparison of isradipine and atenolol. **Angiology** 48: 203-213, 1997

73) Rendell MS, Green SS, Catania A, Oliveto J, Wells J, Banset EJ, Wang H: Post-exercise cutaneous hyperemia resulting from local exercise of an extremity. **Clin Physiol** 17: 213-224, 1997

74) Rendell MS, Milliken BK, Finnegan MF, Finney DE, Healy JC: The skin blood flow response in wound healing. **Microvasc Res** 53: 222-234, 1997

75) Ghazzi MN, Perez, JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, Rendell MS as part of the Troglitazone Study Group, Whitcomb RW: Cardiac and glycemic benefits of troglitazone treatment in NIDDM. **Diabetes** 46: 433-439, 1997

76) Rendell MS, Finnegan MF, Healy JC, Lind A, Milliken BK, Finney DE, Bonner RF: The relationship of laser Doppler skin blood flow measurements to the cutaneous microvascular anatomy. **Microvasc Res** 55: 3-13, 1998

77) Goldberg RB, Einhorn D, Lucas CP, Rendell MS, Damsbo P, Huang WC, Strange P, Brodows RG: A randomized, placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. **Diabetes Care** 21: 1897-1903, 1998

78) Apfel SC, Kessler JA, Adornato BT, Litchy WJ, Sanders C, Rask CA, Rendell M as part of NGF Study Group: Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. **Neurology** 51: 695-702, 1998

79) Rendell M, Hovelson C, O'Connor K, Cheung L, Huard S, Kong TS, Catania A, Rosenthal R: Determination of blood flow in the finger using near infrared spectroscopy. **Clin Physiol** 18: 426 - 434, 1998

80) Rendell MS, Wells J: A comparison of ischemic and pressure induced hyperemia. **Arch**

Phys Med Rehabil 79: 1451-1455, 1998

81) Rendell MS, Milliken BK, Finnegan MF, Finney DE, Healy JC, Bonner RF: The microvascular composition of the healing wound compared at skin sites with nutritive versus arteriovenous perfusion. **J Surg Res** 80: 373-379, 1998

82) Rendell MS, Rajfer J, Wicker P, Smith MD and the Sildenafil Diabetes Study Group: Sildenafil for treatment of erectile dysfunction in men with diabetes. A randomized controlled trial. **JAMA** 281: 421-426, 1999

83) Rendell MS, Finnegan MF, Pisarri T, Healy JC, Lind A, Milliken BK, Finney DE, Bonner RF: A comparison of the cutaneous microvascular properties of the Spontaneously Hypertensive rat and the Wistar Kyoto rat **Comp Biochem Physiol A** 122: 399-406, 1999

84) Rendell M: Book Review of Diabetic Neuropathy, 2nd ed. Dyck & Thomas, **New Engl J Med** 341: 546, 1999

85) Rendell MS, Milliken BK, Finnegan MF, Finney DE, Healy JC, Bonner RF: A comparison of the microvascular response in the healing wound in the spontaneously hypertensive and non-hypertensive rat. **Int J Surg Invest** 2: 17-25, 2000

86) Rendell M: Editorial: Dietary treatment of diabetes mellitus. **N Engl J Med** 342: 1440-1441, 2000

87) Apfel SC, Schwartz S, Adornato BT, Freeman R, Biton V, Rendell M, Vinik A, Giuliani M, Stevens JC, Barbano R, Dyck PJ, and the rhNGF Clinical Investigator Group: A phase III, multicenter, double-blind, placebo controlled, study of the efficacy and safety of recombinant human nerve growth factor in subjects with diabetic polyneuropathy. **JAMA** 284: 2215-2221, 2000

88) Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.Clin Ther. 2000 Dec;22(12):1395-409

89) Rendell MS, Kirchain WR: Drug treatments in type 2 diabetes mellitus. **Annals of Pharmacotherapy** 34: :878-95, 2000.

90) Raskin P, Rendell M, Riddle MC, Dole JF, Salzman A, Rosenstock J: A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin treated type diabetes. **Diabetes Care** 24: 1226-1232, 2001

91) Kipnes MS, Krosnick A, Rendell MS, Egan JW, Mathisen AL, Schneider RL: Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in ;patients with type 2 diabetes mellitus: A randomized placebo-controlled study. **Am J Med** 111: 10-17, 2001

.

92) Apfel SC, Asbury AK, Bril V, Burns TM, Campbell JN, Chalk CH, Dyck PJ, Dyck PJB, Feldman EL, Fields HL, Grant IA, Griffin JW, Klein CJ, Lindblom U, Litchy WJ, Low PA Melanson M, Mendell JR, Merren MD, O'Brien PC, Rendell M, Rizza RA, Service FJ, Thomas PK, Walk D, Wang AK, Wessel K, Windebandk AJ, Ziegler D, Zochodne DW: Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. Ad Hoc Panel on Endpoints for Diabetic Neuropathy Trials. **J Neurol Sci** 189: 3-5, 2001

93) Strandness DE Jr, Dalman RL, Panian S, Rendell MS, Comp PC, Zhang P, Forbes WP. Effect of cilostazol in patients with intermittent claudication: a randomized, double-blind, placebo-controlled study. **Vasc Endovascular Surg** 36:83-91, 2002

94) Rendell M, Johnson ML, Smith D, Finney D, Capp C, Lammers R, Lancaster S: The Skin Blood Flow Response in the Rat Model of Wound Healing: Expression of Vasoactive Factors **J Surg Res** 107: 18-26 (2002)

95) Rendell M, Cariski AT, Hittel N, Zhang P: Cilostazol treatment of claudication in diabetic patients. **Curr Med Res Opin** 18: 479-487, 2002

96) St John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, Patel J, Freed M: A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. **Diabetes Care** 25: 2058-64, 2002

97) Rendell M, Anderson E, Schlueter W, Mailliard J, Honigs D, Rosenthal R. Determination of hemoglobin levels in the finger using near infrared spectroscopy. **Clin Lab Haematol.** 2003; 25:93-97, 2003.

98) Rendell M, Glazer NB, Ye Z: Combination Therapy with Pioglitazone Plus Metformin or Sulfonylurea in Patients with Type 2 Diabetes: Influence of Prior Antidiabetic Drug Regimen**.** **J Diab Complications** 17: 211-217, 2003.

99) Riddle MC, Rosenstock J, Gerich J, Rendell M as part ot the Insulin /Glargine 4002 Study Investigator Group: The Treat to Target Trial. Randomized addition of glargine or human NPH insulin to oral therapyof type 2 diabetic patients**.** **Diab Care** 26: 3080-3086, 2003

100) Rendell M, Saxena S, Shah D: Cutaneous blood flow and peripheral resistance in Type II Diabetes as compared to intermittent claudication patients. **Int J Angiology** 12: 166-171, 2003

101) McKenney JM, Jones PH, Adamcyzk MA, Cain Va, Bryzinski BS, Blasetto W and Rendell M as part of the STELLAR Study Group: Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. **Current Med Res Opinions** 19: 689-696, 2003

102) Jones PH, Davidson MH, Stein EA and Rendell M as part of the STELLAR Study Group: Comparison of the efficacy and safety of rosuvastatin versus atorvastatin , simvastatin

and pravastatin across doses (STELLAR Trial). **Am J Cardiol** 92: 152-160, 2003

103) Capp CL, Dorwart WC, Elias NT, Hillman SR,. Lancaster SS, Nair RC, Ngo BT, Rendell MS, Smith DM: Post Pressure Hyperemia in the Rat. **Comp Biochem Physiol A Mol Integr Physiol**. 137:533-546, 2004

104) Rendell M: Type 2 Diabetes Management in the Elderly Clin Geriatrics 12: 43-52, 2004

105) Bergren DR, Rendell MS: Depressed ventilatory reflexes in response to capsaicin challenge in streptozotocin treated rats**. Life Sciences** 75: 2103-2116, 2004

106) Rendell M. The role of sulphonylureas in the management of type 2 diabetes mellitus. **Drugs**. 64:1339-58, 2004.

107) Rendell M, Lundberg GD:. Advances In Diabetes For The Millennium: An e-Symposium. **Medscape General Medicine**. 2004;6(2). Available at: http://www.medscape.com/viewarticle/484719.

108) Rendell M: Advances in Diabetes for the Millennium: Nutritional Therapy of Type 2 Diabetes. **Medscape General Medicine.** 2004; 6(3s). Available at: http://www.medscape.com/viewprogram/3378.

109) Rendell M: Advances in Diabetes for the Millennium: Drug Therapy of Type 2 Diabetes. **Medscape General Medicine** Available at:http://www.medscape.com/viewprogram/3410.

110) Wigington G, Ngo B, Rendell M: Skin blood flow in diabetic dermopathy. **Arch Dermatol.** 140:1248-50, 2004

111) Ngo BT, Hayes KD, DiMiao DJ, Srinivasan SK, Huerter CJ, Rendell MS. Manifestations of cutaneous diabetic microangiopathy.Am J Clin Dermatol. 2005;6(4):225-37.

112) Rendell M, Vanderhoof J, Venn M, Shehan MA, Arndt E, Rao CS, Gill G, Newman RK, Newman CW. Effect of a barley breakfast cereal on blood glucose and insulin response in normal and diabetic patients. Plant Foods Hum Nutr. 2005;60:63-67.

113) Rendell M: Post-prandial hyperglycemia: Why do we care about it? What should we do? Drug Develop Res 2006; 67: 1-5

114) Rendell MS, Jovanovic L. Targeting postprandial hyperglycemia. Metabolism. 2006; 55: 1263-1281.

115) Rendell M, Gurwitz D: Metabolic syndrome: a wake-up call. Drug Develop Res 2006;

67: 535-538

116) Shah P, Ngo B, Rendell M: Bleeding toes in diabetic neuropathy.Am J Med. 2007; 120: e1-e2

117) Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA.Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care. 2008;31:30-35.

118) Ngo B, Wigington G, Hayes, K,. Huerter,, C, Hillman B, Adler, M, Rendell, M. Skin blood flow in necrobiosis lipoidica diabeticorum. Int J Derm 47: 354-358.2008

119) Rendell M: New drug options for managing diabetes. Diabetes Trends 20: 18-26, 2008

120) Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA. Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. Diabetes Care. 31:30-35, 2008

121) Bergenstal RM, Johnson M, Powers MA, Wynne A, Vlajnic A, Hollander P, Rendell M. Adjust to target in type 2 diabetes: comparison of a simple algorithm with carbohydrate counting for adjustment of mealtime insulin glulisine. Diabetes Care. 31:1305-1310, 2008

122) Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.N Engl J Med. 359:2195-2207, 2008

123) Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK; AVOID Study Investigators.Aliskiren combined with losartan in type 2 diabetes and nephropathy.N Engl J Med. 358:2433-2446.

:

124) Bonebrake R, Casey MJ, Huerter C, Ngo B, O'Brien R, Rendell M.Ethical challenges of pregnancy prevention programs. Cutis 81:494-500, 2008

125) Schwartz SL, Rendell M, Ahmann AJ, Thomas A, Arauz-Pacheco CJ, Welles BR.Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitus. Clin Ther;30:1081-1088, 2008

126) Goykhman S, Drincic A, Desmangles JC, Rendell M. Insulin Glargine: a review 8 years after its introduction. Expert Opin Pharmacother 10:705-718, 2009

127) Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q; Alogliptin Study 007 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. Diabetes Obes Metab. 11:167-176 , 2009

128) Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med. 361:2019-2032, 2009

129) Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 11:1145-1152, 2009

130) Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 009 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Curr Med Res Opin. ;25:2361-237,1, 2009

131) Wymer JP, Simpson J, Sen D, Bongardt S; Lacosamide SP742 Study Group.Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain. 25:376-385 2009

132) Bril V, Hirose T, Tomioka S, Buchanan R; Ranirestat Study Group.Ranirestat for the management of diabetic sensorimotor polyneuropathy. Diabetes Care;32:1256-1260, 2009

133) Andukuri R, Drincic A, Rendell M: Alogliptin: a new addition to the class of DPP-4 inhibitors. Diabetes, Metabolic Disease and Obesity 2: 117 – 126, 2009

134) Bansal A, Chamberlain R, Karr S, Kwasa S, McLaughlin B, Nguyen B, Rendell M, Schmit K, Smith C. A 21 CFR Part 11 Compliant Graphically Based Electronic System for Clinical Research Documentation. J Med Syst. 2010 Nov 25.

135) Ngo B, Rongey C, Hiscox B, Rendell M, Woodley D, Smogorzewski M. Skin blood flow in patients with stage 5 chronic kidney disease on hemodialysis. J Ren Nutr. 2010 Sep;20(5 Suppl):S89-94.

136) Topol EJ, Bousser MG, Fox KA, Creager MA, Despres JP, Easton JD, Hamm CW, Montalescot G, Steg PG, Pearson TA, Cohen E, Gaudin C, Job B, Murphy JH, Bhatt DL; CRESCENDO Investigators. Rimonabant for prevention of cardiovascular events (CRESCENDO): a randomised, multicentre, placebo-controlled trial. Lancet. 2010 Aug 14;376(9740):517-23.

137) Rendell M, Chrysant SG. Review of the safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Postgrad Med. 2011 Jul;123(4):183-186

138) Brugler A, Thompson S, Turner S, Ngo B, Rendell M. Skin blood flow abnormalities in diabetic dermopathy. J. Am Acad Dermatol. 2011 Sep;65(3): 559-63

139) Ratner R, Wynne A, Nakhle S, Brusco O, Vlajnic A, Rendell M. Influence of preprandial versus postprandial insulin glulisine on weight and glycemic control in patients initiating basl-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study (NCT00135096). Diabetes Obex Metab. 2011; 13(12):1142-8 PMID: 21812890

140) Sherry N, Hagopian W, Ludvigsson J, Jain SM, Wahlen J, Ferry RJ Jr., Bode B, Aronoff S, Holland C, Carlin D, King KL, Wilder RL, Pillemer S, Bonvini E, Johnson S, Stein KE, Koenig S, Herold KC, Daifotis AG; Protégé Trial Investigators. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomized, placebo-controlled trial. Lancet. 2011 Aug 6; 378(9790):487-97.

141) Rendell M, Drincic A, Andukuri R. Alogliptin benzoate for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2012 Mar:13(4):553-63.

142) Casey MJ, O'Brien R, Rendell M, Salzman T. Ethical dilemma of mandated contraception in pharmaceutical research at Catholic medical institutions. Am J Bioeth. 2012;12(7):34-37. PMID:22694032

143) Catalona JU, D'Amico AV, Fitzgibbons WF, Kosoko-Lasaki O, Leslie SW, Lynch HT, Moul JW, Rendell MS, Walsh PC. What the U.S. Preventive Services Task Force missed in its prostate cancer screening recommendation. Ann Intern Med. 2012 Jul 17;157(2):137-8.

144) Belzowski A, et al., The effect of vasoactive agents on post-pressure hyperemia, Microvasc. Res. (2012), http://dx.doi.org/10/1016/j.mvr.2012.07.001

145) Rendell M. Of rights and the rules. Obamacare and the challenge of diabetes. Collier's Magazine. October, 2012

146) Rendell S, Kosoko-Lasaki O, Penny G, Cook CT, Sharma A, Austin WP, Rendell M. Improved quality of life in unselected insulin pump-treated children with Type 1 Diabetes in Eastern Nebraska. J Diabetes Sci Technol. 2013 7(2):579-581.

147) Rendell M. The path to approval of new drugs for diabetes. Expert Opin Drug Saf. 2013 Mar;12(2):195-207.

148) Rendell M, Akturk HK, Tella SH. Glargine safety, diabetes and cancer. Expert Opin Drug Saf. 2013 Mar;12(2):247-63.

149) Rendell M. Diabetes. New drug options and old choices. Consultant 2013 April 53(4): 217-227

150) Rendell M, Saiprasad S, Trepp-Carrasco AG, Drincic A. The future of inpatient diabetes management: glucose as the sixth vital sign. Expert Rev. Endocrinol Metab 8(2), 195-205 (2013)

151) Lawson C, Larson K, Van Erdewyck J, Smith C, Rizzo A, Ross L. A facilitated interface to generate a combined textual and graphical database system using widely available software. J Software Engin & Applic 5: 789-796 (2012)

152) Zimmer EA, Welie JVM, Rendell MS: Contraceptives and the Law: A view from a Catholic medical institution. JAMA 309(19) 1999-2000, 2013

153) Rendell M: Insulin degludec: a long-acting modern insulin analog with a predictable

pharmacokinetic/pharmacodynamic profile. Drugs of Today 49(6) 387-397, 2013

154) Alla VM, Agrawal V, DeNazareth A, Mohiuddin S, Ravilla S, Rendell M.
A reappraisal of the risks and benefits of treating to target with cholesterol lowering drugs.
Drugs. 2013 Jul;73(10):1025-54. doi: 10.1007/s40265-013-0072-9.
PMID: 23754124

155) Moul JW, Walsh PC, Rendell MS, Lynch HT, Leslie SW, Kosoko-Lasaki O, Fitzgibbons WP, Powell I, D'Amico AV, Catalona WJ. Re: Early detection of prostate cancer: AUA guideline: H. B. Carter, P. C. Albertsen, M. J. Barry, R. Etzioni, S. J. Freedland, K. L. Greene, L. Holmberg, P. Kantoff, B. R. Konety, M. H. Murad, D. F. Penson and A. L. Zietman J Urol 2013; 190: 419-426. J Urol. 2013 Sep;190(3):1134-7. doi: 10.1016/j.juro.2013.07.002. Epub 2013 Jul 17.
PMID: 23871525

156) White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F; Rendell M as part of EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013 Oct 3;369(14):1327-35. doi: 10.1056/NEJMoa1305889. Epub 2013 Sep 2.
PMID: 23992602

157) Rendell M, Welie JV, Zimmer EA. Controversy over contraception coverage--reply. JAMA. 2013 Sep 25;310(12):1289. doi: 10.1001/jama.2013.276776. PMID: 24065024

158) Tella SH, Akturk HK, Rendell M. Linagliptin for the treatment of Type 2 diabetes. Diabetes Management 4 (1) 85-101 (2014).

159) Beland K , Larson K, T Rowley T, Mueller M, Smith C, Rizzo A, Valandra D, Rendell M. Security and audit trail capabilities of a facilitated interface used to populate a database system with text and graphical data using widely available software. J Software Engineering & Applications, 2014, 7, **-** Published Online July 2014 in SciRes.
http://www.scirp.org/journal/jsea

160) Rendell M. Technosphere inhaled insulin (Afrezza). Drugs Today (Barc). 2014;50(12):813-27

161)Vinik A, Rosenstock J, Sharma U, Feins K, Hsu C, Merante D; DS5565-A-U201 US Phase II Study Investigators Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care. 2014 Dec;37(12):3253-61.

162) Tarasova VD, Zena M, Rendell M. Artifactual hypoglycemia: an old term for a new classification. Diabetes Care. 2014 May;37(5):e85-6.

163) Pratley RE, Nauck MA, Barnett AH, Feinglos MN, Ovalle F, Harman-Boehm I, Ye J, Scott R, Johnson S, Stewart M, Rosenstock J; HARMONY 7 study group. Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. Lancet Diabetes Endocrinol. 2014 Apr;2(4):289-97.

164) Rigby MR, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Patel CM, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Moran A, Russell WE, Pinckney A, Keyes-Elstein L, Howell M, Aggarwal S, Lim N, Phippard D, Nepom GT, McNamara J, Ehlers MR; T1DAL Study Team. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. 2013 Dec;1(4):284-94.

165) Tella SH, Rendell MS.DPP-4 inhibitors: focus on safety. Expert Opin Drug Saf. 2015 Jan;14(1):127-40

166) Tella SH, Rendell MS. Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance. Ther Adv Endocrinol Metab. 2015; 63:109-134

167) Kothny W, Lukashevich V, Foley JE, Rendell MS, Schweizer A. Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial. Diabetologia. 2015 Jun 12. [Epub ahead of print]

168) Bentley-Lewis R, Aguilar D, Riddle MC, Claggett B, Diaz R, Dickstein K, Gerstein HC, Johnston P, Køber LV, Lawson F, Lewis EF, Maggioni AP, McMurray JJ, Ping L, Probstfield JL, Solomon SD, Tardif JC, Wu Y, Pfeffer MA; Rendell as part of ELIXA Investigators. Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo. Am Heart J. 2015 May;169(5):631-638.

169) Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR; as part of TECOS Study Group. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015 Jul 16;373(3):232-42

170) Sands AT, Zambrowicz BP, Rosenstock J, Lapuerta P, Bode BW, Garg SK, Buse JB, Banks P, Heptulla R, Rendell M, Cefalu WT, Strumph P. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes. Diabetes Care. 2015 Jul;38(7):1181-8

171) Rendell M. First fixed-ratio combination of insulin degludec and liraglutide for the

treatment of type 2 diabetes. Drugs Today (Barc). 2015 Mar;51(3):185-96.

172) Rigby MR, Harris KM, Pinckney A, DiMeglio LA, Rendell MS, Felner EI, Dostou JM, Gitelman SE, Griffin KJ, Tsalikian E, Gottlieb PA, Greenbaum CJ, Sherry NA, Moore WV, Monzavi R, Willi SM, Raskin P, Keyes-Elstein L, Long SA, Kanaparthi S, Lim N, Phippard D, Soppe CL, Fitzgibbon ML, McNamara J, Nepom GT, Ehlers MR. Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients. J Clin Invest. 2015 Jul 20

173) Lynch HT, Kosoko-Lasaki O, Leslie SW, Rendell M, Shaw T, Snyder C, D'Amico AV, Buxbaum S, Isaacs WB, Loeb S, Moul JW, Powell I. Screening for Familial and Hereditary Prostate Cancer. Int J Cancer. 2015 Dec 5. doi: 10.1002/ijc.29949. [Epub ahead of print] Review.

174) Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225.

175) Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, Lawson FC, Ping L, Wei X, Lewis EF, Maggioni AP, McMurray JJ, Probstfield JL, Riddle MC, Solomon SD, Tardif JC; Rendell M as ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.N Engl J Med. 2015 Dec 3;373(23):2247-57. doi: 10.1056/NEJMoa1509225.

176) Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; Rendell M as EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720

177) Nauck MA, Stewart MW, Perkins C, Jones-Leone A, Yang F, Perry C, Reinhardt RR, Rendell M. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with

type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetologia. 2015 Nov 17. [Epub ahead of print]

178) Ahrén B, Carr MC, Murphy K, Perkins C, Rendell M, Mallory J, Wilson T, Johnson S. Albiglutide for the treatment of type 2 diabetes mellitus: An integrated safety analysis of the HARMONY phase 3 trials.Diabetes Res Clin Pract. 2017 Apr;126:230-239. doi: 10.1016/j.diabres.2017.02.017

179) Rendell MS. Albiglutide: a unique GLP-1 receptor agonist.
Expert Opin Biol Ther. 2016 Dec;16(12):1557-1569. Epub 2016 Oct 3

180) Rendell M. Conflicts of interest. Financial disclosure. Chapter 14 in Good Clinical Practice: A Question and Answer Reference Guide, editor Earl W. Hulihan, Barnett International, Needham, MA, 2017

PRESENTATIONS, ABSTRACTS

1) Rendell M: Kinetics of Hepatic Adenyl Cyclase with Imidodiphosphate Nucleotides. Presented at **Second International Conference on Cyclic AMP**, Vancouver, Canada, July, 1974

2) Rendell M: Kinetic Analysis of Adenylate Cyclase. Invited Speaker, **Gordon Conference on Hormone Action**, Kimball Union Academy, New Hampshire, August, 1975

3) Schmidt MI, Hadji-Georgopolous A, Rendell M, Margolis S, Plotnick L, Kowarski AA: Hyperglycemia and Associated Free Insulin and Cortisol Changes in "Somogyi"-Like Patients During Continuous Glucose Monitoring. **Clin Res** 27: 24A, 1979

4) Hamilton RG, Rendell M, Adkinson NF Jr: Quantitation of IgG Anti-Insulin Antibodies Using an ^{125}I-Protein A Solid Phase Radioimmunoassay. **Diabetes** 28: 433, 1979

5) Levine MA, Rendell M, Hsu TH, Zadik Z, Kowarski AA: Excessive Urinary Cortisol Excretion in a Euadrenal Patient. **Clin Res** 27: 574A, 1979

6) Rendell M, Zarriello J, Drew HM, Nickoloff E: Endogenous Insulin Secretion in Diet Controlled Maturity Onset Diabetic (MOD) Patients Previously Treated With Insulin. **Clin Res** 28: 404A, 1980

7) Farid RD, Greenberg F, Frank A, Caralis DG, Rendell M, Gillilan R: Non-Invasive Assessment of Left Ventricular Function in Asymptomatic Obese Maturity Onset Diabetics. **Clin Res** 28: 167A, 1980

8) Rendell M, Zarriello J, Drew HM, Nickoloff E: C-Peptide Secretion in Previously Ketonuric Maturity Onset Diabetic (MOD) Patients Successfully Treated by Diet Alone. **Diabetes** 29 (Suppl 2): 102A, 1980

9) Nickoloff E, Drew HM, Hinnenkamp M, Zarriello J, Rendell M: A Comparison of C-Peptide Secretion in Obese Versus Non-Obese Maturity Onset Diabetic (MOD) Patients Controlled by Diet Alone. **Diabetes** 29 (Suppl 2): 102A, 1980

10) Brown MJ, Salmon D, Rendell M: Clonidine Hallucinations. Presented at the **USPHS COA Meeting**, Houston, May, 1980

11) Drew HM, Nickoloff E, Rendell M: The C-Peptide Immunoassay in Serum and Urine Samples. **Ligand Quarterly** 3:45, 1980. Presented at the **Clinical Radioassay Society National Meeting**, May, 1980

12) Rendell M, Hamilton RG, Adkinson NF Jr, Drew HM: Exacerbation of Endogenous Insulin Deficiency by Anti-Bodies to Exogenous Insulin. **Endocrinology** 106 (Suppl 1): 269, 1980. Presented at the **Endocrine Society National Meeting**, June, 1980

13) Rendell M: Diabetes and Nutrition. Presented at the **26th Quarterly Fort Belvoir Family Practice Symposium**, Fort Belvoir, Va, June, 1980

14) Farid RD, Greenberg F, Frank A, Rendell M, Hooper J, Gillilan R: Systolic Time Interval Measurement in Asymptomatic Obese Maturity Onset Diabetics. **Clin Res** 28: 611A, 1980

15) Rendell MS, Zarriello J, Drew HM, Ross DA, Waud J: C-Peptide as a Measure of Insulin Secretion in Maturity Onset Diabetics-Implications for Dietary Control and Reversibility.

Presented at the **Maryland Regional Meeting, American College of Physicians**, October, 1980

16) Rendell MS: Obesity in Maturity Onset Diabetes: Hyperinsulinemia, Insulin Resistance: What Causes It? What Can the Physician Do About It? Presented at **Recent Advances in the Management of Diabetes Mellitus**, Baltimore- Washington International Hotel, October, 1980

17) Rendell M, Zarriello J, Drew HM, Nickoloff E: Endogenous Insulin Secretion in Diet Controlled Maturity Onset Diabetic (MOD) Patients With and Without Normal Glucose Tolerance. **Clin Res** 28, 404A, 1980

18) Ross D, Rendell M, Lassek W, Yamamoto L, Williams J, Smith C, Brown M, Willingmyre L, Kernek S: The Use of Oral Hypoglycemics and Insulin Contrasted in Diabetic American Seamen and non-American Seamen Diabetic OutPatients. Presented at the **USPHS COA Meeting**, Boston, May, 1981

19) Ross D, Rendell M, Lassek WD, Williams J, Kernek S, Yamamoto L, Willingmyre L, Brown MJ: The USPHS ACDS Study: The Frequency of Anti-Hypertensive Drug Use Contrasted in the Diabetic and Non-Diabetic Population. **Clin Res** 29: 325A, 1981

20) Rendell M, Ross D, Lassek WD, Smith C, Brown MJ, Willingmyre L, Williams J, Kernek S: The USPHS ACDS Study: The Frequency of Diuretic Use Contrasted in Diabetic and Non-Diabetic Populations. **Clin Res** 29: 324A, 1981

21) Lassek WD, Ross D, Rendell M, Yamamoto L, Williams J, Brown MJ, Willingmyre L, Smith C, Kernek S: The USPHS ACDS Study: The Frequency of Digitalis Use Contrasted in Diabetic and Non-Diabetic Populations. **Clin Res** 29: 321A, 1981

22) Ross D, Lassek WD, Rendell M, Kernek S, Yamamoto L, Willingmyre L, Brown MJ, Williams J, Smith C: The USPHS ACDS Study: The Use of Anti-Anginal Agents Contrasted in Diabetic and Non-Diabetic Populations. **Clin Res** 29: 324A, 1981

23) Rendell M, Ross D, Lassek WD, Kernek S, Smith C, Williams J, Brown MJ, Willingmyre L, Yamamoto L: The United States Public Health Service (USPHS) Ambulatory Care Data System Study (ACDS): Prevalence of Diabetes Mellitus. **Clin Res** 29: 324A, 1981

24) Salmon D, Rendell M, Waud J, Williams J, Smith C, Ross D, Howard JE: Serum Triiodothyronine Values in L-Thyroxine Treated Patients with High Serum Thyroxine and Clinical Euthyroidism. **Endocrinology** 108: 340, 1981

25) Rendell M, Zarriello J, Drew HM, Dranbauer B, Wilson G, Waud J, Ross D: Recovery From Decompensated Maturity Onset Diabetes Mellitus: Studies of C-Peptide Secretion. **Endocrinology** 108: 344, 1981

26) Hamilton FA, Lundy E, Vickers S, Rendell M: The Effects of Chronic Alcoholism on Maturity Onset Diabetes Mellitus: A Retrospective Study. Presented at the **USPHS COA Meeting**, Boston, May, 1981

27) Rendell M, Meistas MT: Adult Onset Type I Diabetes. **Diabetes** 30 (Suppl 1) 119A, 1981

28) Meistas MT, Rendell M, Margolis S, Kowarski AA: Constant Rate of Urinary C-Peptide Clearance in Fasting and Post- Prandial States of Normal, Obese, and Diabetic Subjects. **Diabetes** 30 (Suppl 1) 121A, 1981

29) Salmon D, Rendell M, Waud J, Williams J, Smith C, Ross D, Howard JE: Serum Triiodothyronine Values in L-Thyroxine Treated Patients with High Serum Thyroxine and Clinical Euthyroidism. Presented at **Maryland American College of Physicians Regional Meeting**, Baltimore, June, 1980

30) Rendell M, Lassek WD, Ross DA, Smith C, Kernek S, Williams J, Brown M, Willingmyre L, Yamamoto L: The United States Public Health Service (USPHS ACDS): A Pharmaceutical Profile of Diabetic Patients. **Diabetes** 31 (Suppl 2) 409, 1982

31) Rendell M, Levine MA, Williams J, Zarriello J: Growth Hormone Release in Maturity Onset Diabetes. **Endocrinology** 110 (Suppl) 378, 1982

32) Rendell M, Lassek WD, Ross DA, Smith C, Kernek S, Williams J, Brown M, Willingmyre L, Yamamoto L: Epidemiologic and Clinical Use of Pharmaceutical Profiles in an Ambulatory Care Data System: Presented at the **Sixth Annual Symposium on Computer Applications in Medical Care**, Washington, D.C., November, 1982

33) Rendell M: C-Peptide Levels as a Criterion in Maturity Onset Diabetes. **Endocrinology** 112 (Suppl) 377, 1983

34) Rendell M, Kao G, Petersen B, Mecherikunnel P, Klenk D, Smith P: A Simple, Clinically Reliable Affinity Column Procedure for Measuring Glycoalbumin. **Diabetes** 32 (Suppl 1) 162A, 1983

35) Rendell M: Diagnosis and Categorization of Diabetes Mellitus. Presented at **Oklahoma State Medical Association Meeting in Association with American Diabetes Association National Program**, May, 1984

36) Rendell M, Valentine JL, Stephen PM, Nierenberg J, Mercer LP, Smith PK: Inhibition of Glycosylation by Acetylation. **Clin Res** 32: 851A, 1984. Presented at **AFCR Southern Society**, New Orleans, January, 1985

37) Rendell M, Rasbold K, Smith PK: Clinical Use of Affinity Chromatography Glycosylated Albumin Measurement. **Clin Res** 32: 851A, 1984. Presented at **AFCR Southern Society**, New Orleans, January, 1985

38) Rendell M, Dodds S, Mercer LP, Stephen PM, Valentine JL, Rasbold K, Nierenberg J, Smith PK. Decreased Glycoalbumin Levels Induced by Aspirin Treatment in the Rat. **Clin Res** 33: 443A, 1985

39) Rendell M: Management of Diabetes and Its Complications in the Elderly. Presented at the **Third Annual Chronically Ill and Aging Conference**, Oklahoma City, November, 1985

40) Rendell M: Is There Anything New in Diabetes. Presented at **Nebraska Chapter, American College of Physicians**, Omaha, March, 1986

41) Rendell M: Glycosylation: Utility as a Marker of Diabetic Control" at the **Conference Diabetic Renal Disease: Special Problems for Native Americans, sponsored by ESRD Network 10, 6th Annual Scientific Session**, Oklahoma City, April, 1986

42) Rendell M: New Developments in Diabetes. Presented at the **Diabetes Workshop, American Diabetes Association, Nebraska Affiliate**, Lincoln, Nebraska, April, 1986

43) Rendell M: Future Developments in Diabetes Treatment. Keynote Speaker at the **Annual Meeting, Minnesota Affiliate, American Diabetes Association**, Minneapolis-St Paul, October 18, 1986

44) Rendell M: New Developments in Diabetes. **Diabetes Workshop, Lincoln County Chapter, Nebraska ADA**, North Platte, Neb, November 1, 1986

45) Rendell M: Diabetes Research in the 80s: **Nebraska-Iowa Society of Medical Technologists 1987 Meeting**, Omaha, Nebraska, May 14, 1987

46) EP Drobny, MS Rendell, DJ Dovgan, TF Bergman, GP O'Donnell, JJ Katims: Mapping Diabetic Sensory Neuropathy by Current Perception Threshold Testing. Presented at **49th Annual Meeting, American Diabetes Association**, Detroit, Michigan, June 4, 1989

47) M Rendell, T Bergman, G O'Donnell, E Drobny, J Borgos, RF Bonner: Skin Microvascular Blood Flow, Volume, and Velocity Measured by Laser Doppler Techniques in Insulin Dependent Diabetes. **Diabetes** 38 (Suppl 2) 125A, 1989

48) Rendell M: Managing Diabetes in the 90's at the **122nd Annual Session of The Nebraska Medical Association**, Omaha, Nebraska, April 27, 1990

49) Rendell M, Fox M, Knox S, Lastovica J, Kirchain W, Meiselman HJ: Diabetic Red Cell Deformability Measured by Cell Transit Time Analysis (CTTA) Presented at **50th Annual Meeting, American Diabetes Association**, Atlanta, Georgia, June 17, 1990

50) Rendell M: Diabetes in the 21st Century at the **Annual Scientific Assembly, Louisiana Academy of Family Physicians**, Destin, Florida, July 30, 1990

51) Rendell M, Fox M, Knox S, Lastovica J, Kirchain W, Meiselman HJ: Diabetic Red Cell Deformability Measured by Cell Transit Time Analysis (CTTA). **Diabetes** 39 (Suppl 1): 33A, 1990

52) Rendell M, Bamisedun O, O'Donnell T, Fulmer J: The Health Care Impact of Diabetes Reflected by the Mutual of Omaha Database. **Diabetes** 40 (Suppl 1) 356A, 1991

53) Rendell M, Bamisedun O, O'Donnell T, Fulmer J: The Health Care Impact of

Diabetes Reflected by the Mutual of Omaha Database. Presented at the **14th International Diabetes Federation Congress**, Washington, D.C., June 25, 1991

54) Rendell M: Co-Chairman of Group on Sensory Measures at the American Diabetes Association Consensus Development Conference on Standardized Measures in Diabetic Neuropathy, Washington, D.C., January 13-16, 1992

55) Rendell M, Bamisedun O: Diabetic cutaneous microangiopathy. Diabetes 1992; 41 (Suppl 1) 177A, Presented at the **52nd Annual Scientific Assembly, American Diabetes Association National Meeting**, San Antonio, Texas, June 23, 1992

56) Rendell M: Hypertension and Diabetes at **Topics in Primary Care for Physicians Assistants**, Omaha, Nebraska, October 3, 1992

57) Rendell M: Alternatives to Insulin Syringes. **Sixth Annual Diabetes Education Workshop, Bergan Mercy Medical Center**, Omaha, Nebraska, October 9, 1992

58) Evans E, Rendell M, Bartek J, Connor S, Bamisedun O, Dovgan D, Giitter M: Thermally induced cutaneous vasodilatation in aging. **Presented at American Geriatric Society National Meeting**, Washington, D.C., November 16, 1992

59) Rendell M: Isradipine in patients with hypertension and diabetes. **Presented at Teaching Consultants Conference on Hypertension**, Dallas, Texas, December 4, 1992

60) Rendell M: Isradipine in patients with hypertension and diabetes. **Presented at Teaching Consultants Conference on Hypertension**, Atlanta, Georgia, January 28, 1993

61) Rendell M, Shehan MA, Bamisedun O, Kahler K: Comparison of the effect of isradipine and atenolol on skin blood flow in diabetic hypertension. **Presented at the Eighth Annual Scientific Meeting of the American Society of Hypertension**, New York, N.Y., May 21, 1993

62) Rendell M, Milliken BS, McIntyre SF, Saterlee MD, Eckermann AJ: Aging of skin blood flow in the rat. Presented at the **51st Annual Scientific Meeting of the American Geriatrics Society**, Los Angeles, California, May 20, 1994

63) Rendell M, McIntyre SF, Terando JV, Kelly ST, Finney DA, Milliken BS, Kingsley DW III, Saterlee MD: The effect of erythropoeitin on skin blood flow in the Spontaneousl Hypertensive Rat as compared to the non-hypertensive Wistar-Kyoto rat. Presented at the **Ninth Annual Scientific Meeting, American Society of Hypertension**, New York, N.Y. May 12, 1994

64) Rendell M, Milliken BK, Lind A, Healey J: Relationship of skin blood flow to composition of the microvascular bed in spontaneously hypertensive (SHR) rats. **Amer J Hypertens** 8: 61A, 1995. Presented at the **Tenth Scientific Meeting, American Society of Hypertension**, New York, N.Y., May 18, 1995

65) Rendell M, Bailey K, Eckermann AJ: Skin blood flow in diabetic hypertension. **Diabetes** 44 (Suppl 1): 61A, 1995. Presented at the **55th Annual Meeting, American Diabetes Association**, Atlanta, Georgia, June 10, 1995

66) Rendell MS, Milliken BK, Banset EJ, Finnegan M, Stanosheck C, Terando JV: the effect of chronic hypertension on skin blood flow. Presented at the **11th Scientific Meeting, American Society of Hypertension**, New York, N.Y., May 16, 1996

67) Rendell MS, Finnegan MT, Pisarri T, Healy JC, Lind A, Milliken BK, Finney DE, Bonner RF. Decreased cutaneous capillary density in the Spontaneously Hypertensive Rat. Presented at the **13th Scientific Meeting, American Society of Hypertension**, New York, N.Y., May 15, 1998 Am J Hypertens 11: 88A, 1998

68) Rendell M, Moreno F: A double-blind, placebo controlled, flexible dose-escalation study assessing the efficacy and safety of sildenafil (VIAGRA^{TM}) in men with erectile dysfunction and diabetes. Presented at the **58th Annual Meeting and Scientific Sessions, American Diabetes Association**, Chicago, Illinois, June 13, 1998 Diabetes 47 (Suppl 1): A9, 1998

69) Rendell M, Vanderhoof J, Venn M, Shehan MA, Arndt E, Rao CS: A grain with reduced blood sugar response in diabetes. Presented at the Annual Meeting of the American Society of Clinical Nutrition, Albuquerque, New, Mexico, October 2, 1998

70) Rendell M, Dole J and the Rosiglitazone Study Group: Rosiglitazone improves glycemic control without adversely affecting cardiac function in type 2 diabetes. Presented at

the 35th Annual Meeting of the EASD, Brussels, Belgium, October 1, 1999

71) Rendell M: Rosiglitazone in the management of type 2 diabetes: A U.S. physician's experience at the Interactive Advisory Meeting for United Kingdom Healthcare Practitioners. Brussels, Belgium September 30, 1999

72) Rendell M: Impotence in diabetes and recent approaches to treatment Presented at Diabetes Mellitus and its Complications. SUNY Buffalo, New York, October 16, 1999

73) Rendell M: La chimotherapie de diabetes. Lausanne, Switzerland, November 15, 1999

74) Rendell M: The chemotherapy of diabetes: Grand Rounds at Baptist Medical Center, Kansas City, Missouri, February 27, 2000

75) Rendell M: Diabetes in the elderly. Grand Rounds at Trinity Hospital, Minot, North Dakota, March 3, 2000

76) Rendell M: Diabetes in the elderly. At the 5th Annual Medical Conference at Medcenter One Health Systems, Bismarck, North Dakota, March 4, 2000

77) Rendell M: Diabetes in the elderly. At the Geriatric Symposium 2000, Avera McKennan Hospital, Sioux City, South Dakota, March 17, 2000

78) Rendell M: Peripheral Arterial Disease. Grand Rounds at Research Medical Center, Kansas City, Kansas, June 21, 2000

79) Rendell M: Clinical Use of Rosiglitazone. At the International Conference on the Glitazones. Munich, Germany, June 30, 2000

80) Rendell M: Sexual Health in Diabetes. At the American Association of Diabetes Educators, San Diego, California, August 9, 2000

81) Rendell M: Guest Speaker Anesthetic and Life Support Drugs Advisory Committee, FDA, Gaithersburg, MD, May 16, 2002

82) Lancaster S, Ngo B, Dorwart W, Rendell M: Fuzzy Pressure, Presented at the Third Annual Diabetes Technology Meeting, San Francisco Airport Hyatt Hotel, November 6, 2003

83) Ngo B, Wiggington G, Rendell M: Skin Blood Flow in Diabetic Dermopathy, Presented at the 2004 Southern California Regional Meeting of the American College of Physicians, Los Angeles, CA

84) Rendell M: The Metabolic Syndrome, Presented at the57th Annual Meeting and Scientific Assembly of the Nebraska Academy of Family Physicians, Omaha, Nebraska April 1, 2005

85) Rendell M: New Treatments for Diabetic Neuropathy Presented at the 21st Annual Diabetes Seminar, Diabetes Education Center of the Midlands, Omaha, Nebraska, April 23, 2005

86) Rendell M: Chairperson: Metabolic Summit Meeting: Drug Discovery and Development, San Francisco, Ca June 28-July 1, 2005

87) Rendell M: Diabetic Neuropathy, Presented at the First Annual Metabolic Summit Meeting: Drug Discovery and Development, San Francisco, Ca June 29, 2005

88) Smogorzewski M, Ngo B, Rendell M, Campese V, Woodley D. Comparison of Skin Conditions in Hypertensive versus Diabetic ESRD on Dialysis. Presented at the American Society of Nephrology, Philadelphia November 8-13, 2005. Journal of the American Society of Nephrology Volume 16, Oct. 2005 Abstracts Issue; PUB447, 879A

89) Ngo B, Smogorewski M, Woodley D, Rendell M: Comparison of skin diseases in diabetic versus non-diabetic end stage renal disease patients, Presented at the 2006 American Academy of Dermatology Annual Meeting, San Francisco, Ca March 6, 2006
J Amer Acad Dermatol P2103 ,2006

90) Ngo B, Hayes K, Huerter C, Rendell M: Skin Blood Flow in Necrobiosis Lipoidica Diabeticorum, Presented at the 2006 American Academy of Dermatology Annual Meeting, San Francisco, Ca March 6, 2006 J Amer Acad Dermatol P2107, 2006

91) Rendell M: Chairman, Second Annual Metabolic Summit Conference, Long Beach, CA, May 18-21, 2006

92) Rendell M: Post-prandial hyperglycemia: Why do we care about it? What should we do?

At the Second Annual Metabolic Summit Conference, Long Beach, CA, May 19, 2006

93) Rendell M: Comparison of Indices of Insulin Resistance and Insulin Secretion between Hypogonadal and Non-Hypogonadal Type II Diabetic Patients. Presented at the American Diabetes Association's 66th Scientific Sessions June 9-13, 2006 in Washington, D.C.

94) Ngo B, Rongey C, Smogorzewski M, Rendell M, Woodley D. Cutaneous blood flow in end-stage renal disease patients. Presented at the American Academy of Dermatology 65th Annual Meeting, Washington DC, Feb 1-4, 2007. J Amer Acad Derm Suppl February 2007, Vol 56(2), p. AB7

95) Rendell M: Keynote Speaker: Cosmopolitan International 81st Annual Meeting, Omaha, NE 9 August 2007

96) Rendell M: Rendell M: Chairman, Third Annual Metabolic Summit Conference, San Diego, CA, November 1,2,2007

97) Smogorzewski M, Rongey C, Hiscox B, Rendell M, Ngo B. Skin Blood Flow in Patients with Stage V CKD on Hemodialysis. Presented at the American Society of Nephrology, San Francisco November 4, 2007. J Am Soc of Nephrol 18: Nov 2007 Abstracts Issue; PUB447, 879A.

98) Rendell M, Ando D: A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects with Diabetic Neuropathy presented at the Second Conference on Drug Delivery and Translational Research. Brooklyn, New York May 13, 2008. Published in Drug Delivery.

99) Ngo B, Hillman B, Thompson S, Hillman S, Turner S, Pisarri T, Rendell M. Stimulatory Effect of Adenosine on Cutaneous Post-Pressure Hyperemia in the Rat. Journal of Investigative Dermatology 2008, Vol 128, S2: Poster 9

100) Panel: Insulin Infusion Pumps: General Hospital and Personal Use Medical Devices Panel, Gaithersburg, MD 5 March 2010

101) Rendell M. Ethnic Health Care Disparity: Focus on Diabetes. Addressing Health Care Disparities: Focus on Diabetes Omaha, NE 17 April 2010

102) Larson K, Lawson C,Van Erdewyck J, Rizzo A, Ross L, Rendell M: Validation and security features of a graphical database interface. Presented at International Conference and Exhibition on Biometrics & Biostatistics March 5-7, 2012 Omaha Marriott, USA

103) Lawson C, Larson K, Van Erdewyck J, Rizzo A, Ross L, Rendell M: A Facilitated Interface for Flexible Database Management using Popular Software. Presented at International Conference and Exhibition on Biometrics & Biostatistics March 5-7, 2012 Omaha Marriott, USA

104) Rendell M, Perkins C, Scott RA, Ye J, Stewart MW, Carr MC, Nauck MA.Harmony 2 Year 3 Results: Albiglutide Monotherapy in Drug-Naïve Patients with T2DM Harmony 2 Year 3 Results: Albiglutide Monotherapy in Drug-Naïve Patients with T2DM. Presented at **74th Scientific Sessions (2014)** June 13 - 17, 2014 - San Francisco, California